USRE49851E1 - Pyridinylaminopyrimidine derivatives, preparation process and use thereof - Google Patents
Pyridinylaminopyrimidine derivatives, preparation process and use thereof Download PDFInfo
- Publication number
- USRE49851E1 USRE49851E1 US17/376,987 US201517376987A USRE49851E US RE49851 E1 USRE49851 E1 US RE49851E1 US 201517376987 A US201517376987 A US 201517376987A US RE49851 E USRE49851 E US RE49851E
- Authority
- US
- United States
- Prior art keywords
- methyl
- amino
- alkyl
- ethyl
- dimethylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title abstract description 7
- LMZLTBMBIZUPOS-UHFFFAOYSA-N n-pyridin-2-ylpyrimidin-2-amine Chemical class N=1C=CC=NC=1NC1=CC=CC=N1 LMZLTBMBIZUPOS-UHFFFAOYSA-N 0.000 title abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 67
- 150000001875 compounds Chemical class 0.000 claims description 217
- -1 haloC1-C4alkyl Chemical group 0.000 claims description 51
- 230000035772 mutation Effects 0.000 claims description 44
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 40
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 36
- 230000002829 reductive effect Effects 0.000 claims description 30
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 29
- 230000003213 activating effect Effects 0.000 claims description 27
- 229910052736 halogen Inorganic materials 0.000 claims description 25
- 150000002367 halogens Chemical class 0.000 claims description 25
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 23
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 21
- 201000005202 lung cancer Diseases 0.000 claims description 21
- 208000020816 lung neoplasm Diseases 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 17
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 16
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 9
- 125000004076 pyridyl group Chemical group 0.000 claims description 9
- 238000006467 substitution reaction Methods 0.000 claims description 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 6
- 125000001041 indolyl group Chemical group 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 5
- 238000005859 coupling reaction Methods 0.000 claims description 5
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 5
- VOLFWQCSTMIDRS-UHFFFAOYSA-N CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)Cl)OC(C)C)C)C Chemical compound CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)Cl)OC(C)C)C)C VOLFWQCSTMIDRS-UHFFFAOYSA-N 0.000 claims description 4
- MRCIBXJONDRDSE-UHFFFAOYSA-N CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)Cl)OCC(F)(F)F)C)C Chemical compound CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)Cl)OCC(F)(F)F)C)C MRCIBXJONDRDSE-UHFFFAOYSA-N 0.000 claims description 4
- LOPNTTFMBXFYBL-UHFFFAOYSA-N CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=CC(=N1)C1=CN(C2=CC(=C(C=C12)F)F)C)OC(C)C)C)C Chemical compound CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=CC(=N1)C1=CN(C2=CC(=C(C=C12)F)F)C)OC(C)C)C)C LOPNTTFMBXFYBL-UHFFFAOYSA-N 0.000 claims description 4
- GHKOONMJXNWOIW-UHFFFAOYSA-N CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)OCC(F)(F)F)C)C Chemical compound CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)OCC(F)(F)F)C)C GHKOONMJXNWOIW-UHFFFAOYSA-N 0.000 claims description 4
- STMTUJKFNQYOPV-UHFFFAOYSA-N N-[2-[2-(dimethylamino)ethyl-methylamino]-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]-6-propan-2-yloxypyridin-3-yl]prop-2-enamide Chemical compound CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)OC(C)C)C)C STMTUJKFNQYOPV-UHFFFAOYSA-N 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 239000007858 starting material Substances 0.000 claims description 4
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims description 3
- VLVAGYOMSSKSKS-UHFFFAOYSA-N CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=C(C(=N1)C1=CN(C2=CC(=C(C=C12)F)F)C)Cl)OC(C)C)C)C Chemical compound CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=C(C(=N1)C1=CN(C2=CC(=C(C=C12)F)F)C)Cl)OC(C)C)C)C VLVAGYOMSSKSKS-UHFFFAOYSA-N 0.000 claims description 3
- AEQZFOSUGQBAKS-UHFFFAOYSA-N CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=C(C(=N1)C1=CN(C2=CC(=C(C=C12)F)F)C)F)OC(C)C)C)C Chemical compound CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=C(C(=N1)C1=CN(C2=CC(=C(C=C12)F)F)C)F)OC(C)C)C)C AEQZFOSUGQBAKS-UHFFFAOYSA-N 0.000 claims description 3
- OVHLZOFQOSOLKU-UHFFFAOYSA-N CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=C(C(=N1)C1=CN(C2=CC(=CC=C12)F)C)Cl)OC(C)C)C)C Chemical compound CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=C(C(=N1)C1=CN(C2=CC(=CC=C12)F)C)Cl)OC(C)C)C)C OVHLZOFQOSOLKU-UHFFFAOYSA-N 0.000 claims description 3
- ZZWYZXSTVQAZJO-UHFFFAOYSA-N CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)F)OCC(F)(F)F)C)C Chemical compound CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)F)OCC(F)(F)F)C)C ZZWYZXSTVQAZJO-UHFFFAOYSA-N 0.000 claims description 3
- BPDLTMVLQDCLIG-UHFFFAOYSA-N CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=C(C(=N1)C=1C=NC(=NC=1)N)Cl)OC(C)C)C)C Chemical compound CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=C(C(=N1)C=1C=NC(=NC=1)N)Cl)OC(C)C)C)C BPDLTMVLQDCLIG-UHFFFAOYSA-N 0.000 claims description 3
- RUTOZFDWGVEMSC-UHFFFAOYSA-N CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=CC(=N1)C1=CN(C2=CC=C(C=C12)F)C)OCC(F)(F)F)C)C Chemical compound CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=CC(=N1)C1=CN(C2=CC=C(C=C12)F)C)OCC(F)(F)F)C)C RUTOZFDWGVEMSC-UHFFFAOYSA-N 0.000 claims description 3
- XWZGFXITMQEERH-UHFFFAOYSA-N N-[2-[2-(dimethylamino)ethyl-methylamino]-5-[[4-(5-fluoro-1-methylindol-3-yl)pyrimidin-2-yl]amino]-6-propan-2-yloxypyridin-3-yl]prop-2-enamide Chemical compound CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=CC(=N1)C1=CN(C2=CC=C(C=C12)F)C)OC(C)C)C)C XWZGFXITMQEERH-UHFFFAOYSA-N 0.000 claims description 3
- BAFBNKPKVNALPX-UHFFFAOYSA-N N-[5-[[4-(5,6-difluoro-1-methylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-6-propan-2-yloxypyridin-3-yl]prop-2-enamide methanesulfonic acid Chemical compound CS(O)(=O)=O.CC(C)Oc1nc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2cc(F)c(F)cc12 BAFBNKPKVNALPX-UHFFFAOYSA-N 0.000 claims description 3
- GPSZIUCISJPDQZ-UHFFFAOYSA-N N-[5-[[5-chloro-4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-6-propan-2-yloxypyridin-3-yl]prop-2-enamide methanesulfonic acid Chemical compound CS(O)(=O)=O.CC(C)Oc1nc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1ncc(Cl)c(n1)-c1cn(C)c2ccccc12 GPSZIUCISJPDQZ-UHFFFAOYSA-N 0.000 claims description 3
- XMIWXISWLCSMDC-UHFFFAOYSA-N N-[5-[[5-chloro-4-(5,6-difluoro-1-methylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-6-propan-2-yloxypyridin-3-yl]prop-2-enamide methanesulfonic acid Chemical compound CS(O)(=O)=O.CC(C)Oc1nc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1ncc(Cl)c(n1)-c1cn(C)c2cc(F)c(F)cc12 XMIWXISWLCSMDC-UHFFFAOYSA-N 0.000 claims description 3
- KEIQLEKQJSMNKB-UHFFFAOYSA-N CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=C(C(=N1)C1=CN(C2=CC=C(C=C12)F)C)Cl)OC(C)C)C)C Chemical compound CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=C(C(=N1)C1=CN(C2=CC=C(C=C12)F)C)Cl)OC(C)C)C)C KEIQLEKQJSMNKB-UHFFFAOYSA-N 0.000 claims description 2
- GCTOYHTZWHYAIE-UHFFFAOYSA-N CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=C(C(=N1)C1=CN(C2=CC=C(C=C12)F)C)F)OC(C)C)C)C Chemical compound CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=C(C(=N1)C1=CN(C2=CC=C(C=C12)F)C)F)OC(C)C)C)C GCTOYHTZWHYAIE-UHFFFAOYSA-N 0.000 claims description 2
- GOWSGVZGRWKAJY-UHFFFAOYSA-N CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)F)OC(C)C)C)C Chemical compound CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)F)OC(C)C)C)C GOWSGVZGRWKAJY-UHFFFAOYSA-N 0.000 claims description 2
- XGAPPKMIXLTHQD-UHFFFAOYSA-N CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=C(C(=N1)C=1C=NN(C=1)C)Cl)OC(C)C)C)C Chemical compound CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=C(C(=N1)C=1C=NN(C=1)C)Cl)OC(C)C)C)C XGAPPKMIXLTHQD-UHFFFAOYSA-N 0.000 claims description 2
- RRFVEOOXGPLTIC-UHFFFAOYSA-N CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=CC(=N1)C1=CN(C2=CC(=CC=C12)F)C)OC(C)C)C)C Chemical compound CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=CC(=N1)C1=CN(C2=CC(=CC=C12)F)C)OC(C)C)C)C RRFVEOOXGPLTIC-UHFFFAOYSA-N 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 5
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 5
- 102000001301 EGF receptor Human genes 0.000 abstract description 54
- 108060006698 EGF receptor Proteins 0.000 abstract description 54
- 206010028980 Neoplasm Diseases 0.000 abstract description 45
- 230000000694 effects Effects 0.000 abstract description 25
- 230000005764 inhibitory process Effects 0.000 abstract description 25
- 239000003814 drug Substances 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 229940124597 therapeutic agent Drugs 0.000 abstract description 5
- 230000009702 cancer cell proliferation Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 60
- 230000015572 biosynthetic process Effects 0.000 description 53
- 238000003786 synthesis reaction Methods 0.000 description 53
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 50
- 238000005160 1H NMR spectroscopy Methods 0.000 description 48
- 239000000203 mixture Substances 0.000 description 47
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 239000011541 reaction mixture Substances 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 21
- 239000007787 solid Substances 0.000 description 21
- 201000011510 cancer Diseases 0.000 description 19
- 229940121647 egfr inhibitor Drugs 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 241000699660 Mus musculus Species 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 238000011580 nude mouse model Methods 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 102200048955 rs121434569 Human genes 0.000 description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 8
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000002427 irreversible effect Effects 0.000 description 8
- 229960003278 osimertinib Drugs 0.000 description 8
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 7
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 102200048928 rs121434568 Human genes 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 5
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 5
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 5
- 229960001686 afatinib Drugs 0.000 description 5
- 229940041181 antineoplastic drug Drugs 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 229960001433 erlotinib Drugs 0.000 description 5
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 5
- 229960002584 gefitinib Drugs 0.000 description 5
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- SXQCTESRRZBPHJ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O SXQCTESRRZBPHJ-UHFFFAOYSA-M 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000012746 preparative thin layer chromatography Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- HYXNZAYHQJAPIT-UHFFFAOYSA-N CN(C1=NC(=C(C=C1[N+](=O)[O-])N)OC(C)C)CCN(C)C Chemical compound CN(C1=NC(=C(C=C1[N+](=O)[O-])N)OC(C)C)CCN(C)C HYXNZAYHQJAPIT-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000009465 Growth Factor Receptors Human genes 0.000 description 3
- 108010009202 Growth Factor Receptors Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 229910002666 PdCl2 Inorganic materials 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229910019020 PtO2 Inorganic materials 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 3
- 229950002205 dacomitinib Drugs 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- HVOYZOQVDYHUPF-UHFFFAOYSA-N n,n',n'-trimethylethane-1,2-diamine Chemical compound CNCCN(C)C HVOYZOQVDYHUPF-UHFFFAOYSA-N 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- GIKMWFAAEIACRF-UHFFFAOYSA-N 2,4,5-trichloropyrimidine Chemical compound ClC1=NC=C(Cl)C(Cl)=N1 GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 description 2
- SHCWQWRTKPNTEM-UHFFFAOYSA-N 2,6-dichloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1Cl SHCWQWRTKPNTEM-UHFFFAOYSA-N 0.000 description 2
- MBYZPCLOMQCIEV-UHFFFAOYSA-N 3-(2,5-dichloropyrimidin-4-yl)-1-methylindole Chemical compound C12=CC=CC=C2N(C)C=C1C1=NC(Cl)=NC=C1Cl MBYZPCLOMQCIEV-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- HXUSBUUXEFHDQR-UHFFFAOYSA-N 5-N-[5-chloro-4-(1-methylindol-3-yl)pyrimidin-2-yl]-2-N-[2-(dimethylamino)ethyl]-2-N-methyl-3-nitro-6-propan-2-yloxypyridine-2,5-diamine Chemical compound CN(C1=NC(=C(C=C1[N+](=O)[O-])NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)Cl)OC(C)C)CCN(C)C HXUSBUUXEFHDQR-UHFFFAOYSA-N 0.000 description 2
- BLTIODQUDUXFKH-UHFFFAOYSA-N 5-N-[5-chloro-4-(1-methylindol-3-yl)pyrimidin-2-yl]-2-N-[2-(dimethylamino)ethyl]-2-N-methyl-6-propan-2-yloxypyridine-2,3,5-triamine Chemical compound CN(C1=NC(=C(C=C1N)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)Cl)OC(C)C)CCN(C)C BLTIODQUDUXFKH-UHFFFAOYSA-N 0.000 description 2
- OVVBXVJFGCFEFK-UHFFFAOYSA-N 6-chloro-2-methoxy-3-nitropyridine Chemical compound COC1=NC(Cl)=CC=C1[N+]([O-])=O OVVBXVJFGCFEFK-UHFFFAOYSA-N 0.000 description 2
- NBYVIQCFOQQXPZ-UHFFFAOYSA-N 6-chloro-2-methoxypyridin-3-amine Chemical compound COC1=NC(Cl)=CC=C1N NBYVIQCFOQQXPZ-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 2
- MUCYUWICGUWYQT-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N(C(C)=O)C=1C(=NC(=C(C=1)[N+](=O)[O-])N(C)CCN(C)C)OC(C)C Chemical compound C(C)(C)(C)OC(=O)N(C(C)=O)C=1C(=NC(=C(C=1)[N+](=O)[O-])N(C)CCN(C)C)OC(C)C MUCYUWICGUWYQT-UHFFFAOYSA-N 0.000 description 2
- DXNFYDVDASLDKP-UHFFFAOYSA-N CN(C1=NC(=C(C=C1[N+](=O)[O-])N)OCC(F)(F)F)CCN(C)C Chemical compound CN(C1=NC(=C(C=C1[N+](=O)[O-])N)OCC(F)(F)F)CCN(C)C DXNFYDVDASLDKP-UHFFFAOYSA-N 0.000 description 2
- NKLPYUKYTUDVRY-UHFFFAOYSA-N CN(C1=NC(=C(C=C1[N+](=O)[O-])NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)OC(C)C)CCN(C)C Chemical compound CN(C1=NC(=C(C=C1[N+](=O)[O-])NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)OC(C)C)CCN(C)C NKLPYUKYTUDVRY-UHFFFAOYSA-N 0.000 description 2
- JEWIWGGCEDQFSM-UHFFFAOYSA-N CN(CCN(C1=C(C=C(C(=N1)OC(C)C)NC(C)=O)[N+](=O)[O-])C)C Chemical compound CN(CCN(C1=C(C=C(C(=N1)OC(C)C)NC(C)=O)[N+](=O)[O-])C)C JEWIWGGCEDQFSM-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- WVZKVXLWVBFKKB-UHFFFAOYSA-N Cl.CN(C1=NC(=C(C=C1[N+](=O)[O-])N)OC)CCN(C)C Chemical compound Cl.CN(C1=NC(=C(C=C1[N+](=O)[O-])N)OC)CCN(C)C WVZKVXLWVBFKKB-UHFFFAOYSA-N 0.000 description 2
- SEVVEEDDRVMCLZ-UHFFFAOYSA-N ClC1=C(C=C(C(=N1)OC(C)C)NC(C)=O)[N+](=O)[O-] Chemical compound ClC1=C(C=C(C(=N1)OC(C)C)NC(C)=O)[N+](=O)[O-] SEVVEEDDRVMCLZ-UHFFFAOYSA-N 0.000 description 2
- PWBSCYNWZINOSE-UHFFFAOYSA-N ClC1=C(C=C(C(=N1)OC)NC(C)=O)[N+](=O)[O-] Chemical compound ClC1=C(C=C(C(=N1)OC)NC(C)=O)[N+](=O)[O-] PWBSCYNWZINOSE-UHFFFAOYSA-N 0.000 description 2
- VVHXGFLAARAFIU-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C1=CN(C2=CC(=CC=C12)F)C)Cl Chemical compound ClC1=NC=C(C(=N1)C1=CN(C2=CC(=CC=C12)F)C)Cl VVHXGFLAARAFIU-UHFFFAOYSA-N 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- YFLZCOSQFKCTQR-UHFFFAOYSA-N N-(6-chloro-2-methoxypyridin-3-yl)acetamide Chemical compound ClC1=CC=C(C(=N1)OC)NC(C)=O YFLZCOSQFKCTQR-UHFFFAOYSA-N 0.000 description 2
- YRNNOEXKEDQYTD-UHFFFAOYSA-N NC=1C=C(C(=NC=1N(C)CCN(C)C)OC(C)C)NC(OC(C)(C)C)=O Chemical compound NC=1C=C(C(=NC=1N(C)CCN(C)C)OC(C)C)NC(OC(C)(C)C)=O YRNNOEXKEDQYTD-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000009982 effect on human Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000006266 etherification reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 description 2
- 229950008835 neratinib Drugs 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000005936 piperidyl group Chemical group 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229950009855 rociletinib Drugs 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229910052979 sodium sulfide Inorganic materials 0.000 description 2
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- KZEDPVFJLQLDIZ-UHFFFAOYSA-N (5-diphenylphosphanyl-9,9-dimethylxanthen-4-yl)-diphenylphosphane Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1.C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZEDPVFJLQLDIZ-UHFFFAOYSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- BLRHMMGNCXNXJL-UHFFFAOYSA-N 1-methylindole Chemical compound C1=CC=C2N(C)C=CC2=C1 BLRHMMGNCXNXJL-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 1
- UWXMFPQBPKPCJM-UHFFFAOYSA-N 2-N-[2-(dimethylamino)ethyl]-5-N-[4-(5-fluoro-1-methylindol-3-yl)pyrimidin-2-yl]-2-N-methyl-3-nitro-6-propan-2-yloxypyridine-2,5-diamine Chemical compound CN(C1=NC(=C(C=C1[N+](=O)[O-])NC1=NC=CC(=N1)C1=CN(C2=CC=C(C=C12)F)C)OC(C)C)CCN(C)C UWXMFPQBPKPCJM-UHFFFAOYSA-N 0.000 description 1
- UTWWHDZLZMIZHU-UHFFFAOYSA-N 2-N-[2-(dimethylamino)ethyl]-5-N-[4-(5-fluoro-1-methylindol-3-yl)pyrimidin-2-yl]-2-N-methyl-6-propan-2-yloxypyridine-2,3,5-triamine Chemical compound CN(C1=NC(=C(C=C1N)NC1=NC=CC(=N1)C1=CN(C2=CC=C(C=C12)F)C)OC(C)C)CCN(C)C UTWWHDZLZMIZHU-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006029 2-methyl-2-butenyl group Chemical group 0.000 description 1
- 125000006049 2-methyl-2-pentenyl group Chemical group 0.000 description 1
- KAHYDAVMWMQPDG-UHFFFAOYSA-N 3-(2-chloro-5-fluoropyrimidin-4-yl)-1-methylindole Chemical compound C12=CC=CC=C2N(C)C=C1C1=NC(Cl)=NC=C1F KAHYDAVMWMQPDG-UHFFFAOYSA-N 0.000 description 1
- IIBWXYHPBMUNJP-UHFFFAOYSA-N 3-(2-chloropyrimidin-4-yl)-1-methylindole Chemical compound C12=CC=CC=C2N(C)C=C1C1=CC=NC(Cl)=N1 IIBWXYHPBMUNJP-UHFFFAOYSA-N 0.000 description 1
- MFIXYHCHRCLVBH-UHFFFAOYSA-N 3-(2-chloropyrimidin-4-yl)-5,6-difluoro-1-methylindole Chemical compound ClC1=NC=CC(=N1)C1=CN(C2=CC(=C(C=C12)F)F)C MFIXYHCHRCLVBH-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- AKQFWRKRSAJNGL-UHFFFAOYSA-N 5-N-[4-(5,6-difluoro-1-methylindol-3-yl)pyrimidin-2-yl]-2-N-[2-(dimethylamino)ethyl]-2-N-methyl-3-nitro-6-propan-2-yloxypyridine-2,5-diamine Chemical compound CN(C1=NC(=C(C=C1[N+](=O)[O-])NC1=NC=CC(=N1)C1=CN(C2=CC(=C(C=C12)F)F)C)OC(C)C)CCN(C)C AKQFWRKRSAJNGL-UHFFFAOYSA-N 0.000 description 1
- FLEQZVCGXZZXTI-UHFFFAOYSA-N 6-chloro-2-(2,2,2-trifluoroethoxy)pyridin-3-amine Chemical compound ClC1=CC=C(C(=N1)OCC(F)(F)F)N FLEQZVCGXZZXTI-UHFFFAOYSA-N 0.000 description 1
- KLUIBCHLQSALCA-UHFFFAOYSA-N 6-chloro-2-propan-2-yloxypyridin-3-amine Chemical compound ClC1=CC=C(C(=N1)OC(C)C)N KLUIBCHLQSALCA-UHFFFAOYSA-N 0.000 description 1
- ZJUQBSZTBLOKFQ-UHFFFAOYSA-N 6-chloro-3-nitro-2-(2,2,2-trifluoroethoxy)pyridine Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1OCC(F)(F)F ZJUQBSZTBLOKFQ-UHFFFAOYSA-N 0.000 description 1
- DKFKAZUTHFILIQ-UHFFFAOYSA-N 6-chloro-3-nitro-2-propan-2-yloxypyridine Chemical compound CC(C)OC1=NC(Cl)=CC=C1[N+]([O-])=O DKFKAZUTHFILIQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- ULXXDDBFHOBEHA-ONEGZZNKSA-N Afatinib Chemical compound N1=CN=C2C=C(OC3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-ONEGZZNKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- MBXYOKFHZQTAQY-UHFFFAOYSA-N CN(C1=NC(=C(C=C1N)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)Cl)OCC(F)(F)F)CCN(C)C Chemical compound CN(C1=NC(=C(C=C1N)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)Cl)OCC(F)(F)F)CCN(C)C MBXYOKFHZQTAQY-UHFFFAOYSA-N 0.000 description 1
- QPFJYZIYMHGGKA-UHFFFAOYSA-N CN(C1=NC(=C(C=C1N)NC1=NC=CC(=N1)C1=CN(C2=CC(=C(C=C12)F)F)C)OC(C)C)CCN(C)C Chemical compound CN(C1=NC(=C(C=C1N)NC1=NC=CC(=N1)C1=CN(C2=CC(=C(C=C12)F)F)C)OC(C)C)CCN(C)C QPFJYZIYMHGGKA-UHFFFAOYSA-N 0.000 description 1
- LRYNDHSAJDHLRC-UHFFFAOYSA-N CN(C1=NC(=C(C=C1N)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)OCC(F)(F)F)CCN(C)C Chemical compound CN(C1=NC(=C(C=C1N)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)OCC(F)(F)F)CCN(C)C LRYNDHSAJDHLRC-UHFFFAOYSA-N 0.000 description 1
- OGFFTWXCSKJGRY-UHFFFAOYSA-N CN(C1=NC(=C(C=C1[N+](=O)[O-])NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)Cl)OCC(F)(F)F)CCN(C)C Chemical compound CN(C1=NC(=C(C=C1[N+](=O)[O-])NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)Cl)OCC(F)(F)F)CCN(C)C OGFFTWXCSKJGRY-UHFFFAOYSA-N 0.000 description 1
- LZHJMXLAMKAISA-UHFFFAOYSA-N CN(C1=NC(=C(C=C1[N+](=O)[O-])NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)OCC(F)(F)F)CCN(C)C Chemical compound CN(C1=NC(=C(C=C1[N+](=O)[O-])NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)OCC(F)(F)F)CCN(C)C LZHJMXLAMKAISA-UHFFFAOYSA-N 0.000 description 1
- USQDVKSAOJFRIK-UHFFFAOYSA-N CN(CCN(C1=C(C=C(C(=N1)OC)NC(C)=O)[N+](=O)[O-])C)C Chemical compound CN(CCN(C1=C(C=C(C(=N1)OC)NC(C)=O)[N+](=O)[O-])C)C USQDVKSAOJFRIK-UHFFFAOYSA-N 0.000 description 1
- ADLRXHCFFZXWDJ-UHFFFAOYSA-N CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=C(C(=N1)C=1C=NC(=NC=1)OC)Cl)OC(C)C)C)C Chemical compound CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=C(C(=N1)C=1C=NC(=NC=1)OC)Cl)OC(C)C)C)C ADLRXHCFFZXWDJ-UHFFFAOYSA-N 0.000 description 1
- XCPNBTMXIYTBJQ-UHFFFAOYSA-N CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)C4(CC(=C(N=C4)N)N)N Chemical compound CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)C4(CC(=C(N=C4)N)N)N XCPNBTMXIYTBJQ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- IDODOLUUPZHQQW-UHFFFAOYSA-N ClC1=C(C=C(C(=N1)OCC(F)(F)F)NC(C)=O)[N+](=O)[O-] Chemical compound ClC1=C(C=C(C(=N1)OCC(F)(F)F)NC(C)=O)[N+](=O)[O-] IDODOLUUPZHQQW-UHFFFAOYSA-N 0.000 description 1
- AWGYHDMBWUEMPE-UHFFFAOYSA-N ClC1=CC=C(C(=N1)OC(C)C)NC(C)=O Chemical compound ClC1=CC=C(C(=N1)OC(C)C)NC(C)=O AWGYHDMBWUEMPE-UHFFFAOYSA-N 0.000 description 1
- IOVBPEIIPCRDFZ-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C1=CN(C2=CC(=C(C=C12)F)F)C)Cl Chemical compound ClC1=NC=C(C(=N1)C1=CN(C2=CC(=C(C=C12)F)F)C)Cl IOVBPEIIPCRDFZ-UHFFFAOYSA-N 0.000 description 1
- NKPIKQQMHGJOOD-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C1=CN(C2=CC(=C(C=C12)F)F)C)F Chemical compound ClC1=NC=C(C(=N1)C1=CN(C2=CC(=C(C=C12)F)F)C)F NKPIKQQMHGJOOD-UHFFFAOYSA-N 0.000 description 1
- OVCLHBXVUMSLAW-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C1=CN(C2=CC=C(C=C12)F)C)Cl Chemical compound ClC1=NC=C(C(=N1)C1=CN(C2=CC=C(C=C12)F)C)Cl OVCLHBXVUMSLAW-UHFFFAOYSA-N 0.000 description 1
- UFXRSSABABZTJL-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C1=CN(C2=CC=C(C=C12)F)C)F Chemical compound ClC1=NC=C(C(=N1)C1=CN(C2=CC=C(C=C12)F)C)F UFXRSSABABZTJL-UHFFFAOYSA-N 0.000 description 1
- IZKDAIYQXPQCMF-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C=1C=NC(=NC=1)N)Cl Chemical compound ClC1=NC=C(C(=N1)C=1C=NC(=NC=1)N)Cl IZKDAIYQXPQCMF-UHFFFAOYSA-N 0.000 description 1
- IBGWWFJOBWJHBZ-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C=1C=NC(=NC=1)OC)Cl Chemical compound ClC1=NC=C(C(=N1)C=1C=NC(=NC=1)OC)Cl IBGWWFJOBWJHBZ-UHFFFAOYSA-N 0.000 description 1
- PJTTYAVJLKCKBM-UHFFFAOYSA-N ClC1=NC=CC(=N1)C1=CN(C2=CC(=CC=C12)F)C Chemical compound ClC1=NC=CC(=N1)C1=CN(C2=CC(=CC=C12)F)C PJTTYAVJLKCKBM-UHFFFAOYSA-N 0.000 description 1
- IWSQUJGGLUWCQE-UHFFFAOYSA-N ClC1=NC=CC(=N1)C1=CN(C2=CC=C(C=C12)F)C Chemical compound ClC1=NC=CC(=N1)C1=CN(C2=CC=C(C=C12)F)C IWSQUJGGLUWCQE-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 101150039808 Egfr gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- QGHGVHDVZWCWPQ-UHFFFAOYSA-N N-[6-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-nitropyridin-3-yl]acetamide hydrochloride Chemical compound Cl.COc1nc(N(C)CCN(C)C)c(cc1NC(C)=O)[N+]([O-])=O QGHGVHDVZWCWPQ-UHFFFAOYSA-N 0.000 description 1
- PPQACIQMAISYTP-UHFFFAOYSA-N N-[6-[2-(dimethylamino)ethyl-methylamino]-5-nitro-2-(2,2,2-trifluoroethoxy)pyridin-3-yl]acetamide Chemical compound CN(CCN(C1=C(C=C(C(=N1)OCC(F)(F)F)NC(C)=O)[N+](=O)[O-])C)C PPQACIQMAISYTP-UHFFFAOYSA-N 0.000 description 1
- GHKKZQRLKUVBEC-UHFFFAOYSA-N N1(C)C=C(C2=NC(=NC=C2Cl)Cl)C=N1 Chemical compound N1(C)C=C(C2=NC(=NC=C2Cl)Cl)C=N1 GHKKZQRLKUVBEC-UHFFFAOYSA-N 0.000 description 1
- UQXIAWDSIAFDHF-UHFFFAOYSA-N NC=1C=C(C(=NC=1N(C)CCN(C)C)OCC(F)(F)F)NC(OC(C)(C)C)=O Chemical compound NC=1C=C(C(=NC=1N(C)CCN(C)C)OCC(F)(F)F)NC(OC(C)(C)C)=O UQXIAWDSIAFDHF-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- PQGAIXAUQIPWOU-UHFFFAOYSA-M O1CCOCC1.O1CCOCC1.C(C)(=O)[O-].[K+] Chemical compound O1CCOCC1.O1CCOCC1.C(C)(=O)[O-].[K+] PQGAIXAUQIPWOU-UHFFFAOYSA-M 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229930188522 aclacinomycin Natural products 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- DKPBWQKQXNICDH-UHFFFAOYSA-N aniline;quinazoline Chemical compound NC1=CC=CC=C1.N1=CN=CC2=CC=CC=C21 DKPBWQKQXNICDH-UHFFFAOYSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 150000004656 dimethylamines Chemical class 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 150000003947 ethylamines Chemical class 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 150000003956 methylamines Chemical class 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- LPNBBFKOUUSUDB-UHFFFAOYSA-N p-toluic acid Chemical compound CC1=CC=C(C(O)=O)C=C1 LPNBBFKOUUSUDB-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 229940023569 palmate Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229950006299 pelitinib Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011257 shell material Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical class CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Definitions
- the present invention relates to pyridinylaminopyrimidine derivatives, which selectively inhibit the activity of mutation-type epidermal growth factor receptor (EGFR), a pharmaceutically acceptable salt thereof, a process for preparing the same, a pharmaceutical composition containing said derivative and a pharmaceutically acceptable salt thereof, uses of said derivative and a pharmaceutically acceptable salt thereof in treating some mutation-type EGFR mediated diseases and in manufacture of a medicament for treating some mutation-type EGFR mediated diseases.
- EGFR epidermal growth factor receptor
- Cancer has been considered as a disease of the intracellular signal transconducing system or signal transduction mechanism.
- the most common cause of cancer is a series of defects, either in proteins, when they are mutated, or in the regulation of the quantities of the proteins in the cells such that they are over or under produced. Mutations to the cell surface receptors, which usually transduce the signals into the cells by means of tyrosine kinases, can lead to activation of the kinase in the absence of ligand, and passing of a signal which does not really exist. Alternatively, many receptor tyrosine kinases can be overexpressed on the cell surface leading to an inappropriately strong response to a weak signal.
- Epidermal cell growth factors receptors are identified as one significant driving factor in the process for cellular growth and proliferation.
- the epidermal cell growth factors receptors family is composed of EGFR (Erb-B1), Erb-B2 (HER-2/neu), Erb-B3 and Erb-B4.
- the epidermal cell growth factors receptors are concerned in the process for most cancers, such as lung cancer, colon cancer and breast cancer.
- the overexpression and mutation of EGFR have been proved to be the leading risk factor for a breast cancer with poor prognosis.
- each of the above four members of the receptors family can aggregate with another member into a heterodimer, and form a signal transduction complex. Overexpression of one or more member(s) of this family in a malignant tumor will result in a synergistic signal transduction.
- EGFR belongs to the protein tyrosine kinase (PTK) family.
- the protein tyrosine kinase is an group of enzymes which catalyze the transportation of phosphate groups from adenosine triphosphate (ATP) to the tyrosine residue located in a protein substrate.
- ATP adenosine triphosphate
- Protein tyrosine kinases function in normal cell growth.
- the overexpression and mutation of EGFR may cause the activation of receptors without ligands and the phosphorylation of some proteins, and then the signal for cell division is produced. As a result, EGFR may magnify the weak signal excessively by its own tyrosine-kinase action, and render the overproliferation of cells.
- PTK inhibitors as a potential anti-cancer therapeutic drug are of wide concern.
- Typical representatives of currently market available EGFR reversible inhibitors include Gefitinib, Erlotinib and Lapatinib, and inhibit the EGFR wild-type and activating mutations (e.g. Exon 19 deletion activating mutation, or L858R activating mutation).
- Their structures are as follows, and are respectively useful for treating non-small cell lung cancer (NSCLC) and breast cancer.
- NSCLC non-small cell lung cancer
- Clinical study proves gefitinib and erlotinib have a favorable therapeutic effect on NSCLC patients with EGFR exon 19 deletion or L858R mutation.
- NSCLC non-small cell lung cancer
- erlotinib have a favorable therapeutic effect on NSCLC patients with EGFR exon 19 deletion or L858R mutation.
- their limitations are that patients develop drug resistance after treatment, so that inhibitors of this type are limited in their further clinical applications.
- T790M is located at the entrance of the ATP binding pocket of EGFR, and the size of its side chain directly affects the ability of EGFR binding to ATP.
- the T790M mutation spatially inhibits the interaction of the EGFR inhibitor and the ATP binding site, increases the affinity of EGFR to ATP, and makes the cells resistant to the EGFR inhibitors.
- irreversible EGFR inhibitors Compared to reversible EGFR inhibitors, irreversible EGFR inhibitors have very prominent advantages. Irreversible EGFR inhibitors can inhibit EGFR for a long time and are only limited by the normal rate of receptor re-binding (also called reversion). It is found that the irreversible EGFR inhibitor can covalently bind to the cysteine residue (Cys797) of the EGFR by Michael addition reaction and expand the binding sites of irreversible EGFR inhibitors and the ATP, so that the resistance caused by the T790M mutation can be overcame to some extent (Li D et al., Oncogenc, 27:4702-4711, 2008).
- the above-mentioned reversible or irreversible EGFR inhibitors being currently marketed or under development, are mainly quinazoline compounds.
- the currently reported quinazoline EGFR inhibitors are the ATP competitive inhibitors of wild-type EGFR, leading to the occurrence of some side-reaction.
- a group of pyrimidine-based irreversible EGFR inhibitors which are specific to the EGFR T790M was reported by the researchers, and the structures are shown below.
- these pyrimidine-based compounds Compared to the existing aniline quinazoline EGFR inhibitors, these pyrimidine-based compounds have a 30-100 fold higher inhibition activity for the EGFR T790M, and a 100 fold lower inhibition activity for the wild-type EGFR (WenjunZhou et al., Nature, 462:1070-1074, 2009). However, these pyrimidine-based compounds did not enter the clinical study later.
- the present invention provides a compound represented by the following general formula (I), or a pharmaceutically acceptable salt thereof:
- Ring A is aryl or heteroaryl
- R 1 is selected from a group consisting of hydrogen, halogen, C 1 -C 4 alkyl, haloC 1 -C 4 -alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl or —CN
- R 2 is selected from a group consisting of C 1 -C 4 alkyl, haloC 1 -C 4 -alkyl, C 2 -C 6 alkenyl, —(CH 2 ) q OR 7 , —(CH 2 ) q NR 7 R 7 ′ or —(CH 2 ) q C(O)R 7 ;
- Each R 5 is dependently independently halogen, C 1 -C 4 alkyl, haloC 1 -C 4 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, —OR 6 , —C(O)R 7 , —C(O)NR 7 R 7 ′, —OR 7 , —NR 7 R 7 ′, —CN or —NO 2 ;
- R 3 is selected from a group consisting of halogen, —CN, —NO 2 , C 1 -C 4 alkyl, haloC 1 -C 4 alkyl, —C(O)R 6 , —C(O)R 7 , —C(O)NR 7 R 7 ′, —OR 7 , —OR 6 , —NHR 7 , —NR 7 -(C 1 -C 4 alkyl), —NR 7 -(haloC 1 -C 4 alkyl), —NR 7 (
- the present invention provides a compound represented by the general formula (I), which can inhibit one or more EGFR activating or resistant mutations, such as L858R activating mutation, Exon 19 deletion activating mutation, and T790M resistant mutation.
- the present compound can be useful in treating the cancer patient who has been resistant to the existing therapy based on the EGFR inhibitor.
- the present invention provides a compound represented by the general formula (I), which shows a higher inhibition to the activating or resistant mutation-type EGFR than the wild-type EGFR. Due to the reduced toxicity associated with the inhibition of the wild-type EGFR, it is therefore expected that the compound of the present invention is more useful as a therapeutic agent, in particular for treating the cancer.
- the present invention also provides a process for preparing the compound represented by the general formula (I) of the present invention.
- the present invention also provides a pharmaceutical composition, comprising the compound represented by the general formula (I) of the present invention or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, excipient or diluent.
- the present invention also provides use of the compound represented by the general formula (I) of the present invention or a pharmaceutically acceptable salt thereof for treating an EGFR activating or resistant mutation-mediated disease, in particular cancer, in mammals, in particular human.
- the present invention also provides use of the compound represented by the general formula (I) of the present invention or a pharmaceutically acceptable salt thereof in manufacture of a medicament for treating an EGFR activating or resistant mutation-mediated disease, in particular cancer, in mammals, in particular human.
- the present invention also provides a method for treating an EGFR activating or resistant mutation-mediated disease, in particular cancer, in mammals, in particular human, said method comprises administrating to a patient the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising a therapeutically effective amount of the compound represented by the general formula (I) and a pharmaceutically acceptable carrier, excipient or diluent.
- the present invention also provides a method of selectively inhibiting the EGFR activating or resistant mutation over the wild-type EGFR (WT EGFR), said method comprises contacting a biological sample with or administrating to a patient the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same.
- the cancer as mentioned in the present invention can be selected from a group consisting of lung cancer, ovarian cancer, cervical cancer, breast cancer, stomach cancer, colorectal cancer, pancreatic cancer, glioma, glioblastoma, melanoma, prostate cancer, leukemia, lymphoma, nonHodgkin's lymphoma, hepatocytes cancer, gastrointestinal stromal tumor (GIST), thyroid cancer, cholangiocarcinoma, endometrial cancer, renal cancer, anaplastic large cell lymphoma, acute myeloid leukemia (AML), multiple myeloma, and mesothelioma.
- lung cancer ovarian cancer, cervical cancer, breast cancer, stomach cancer, colorectal cancer, pancreatic cancer, glioma, glioblastoma, melanoma, prostate cancer, leukemia, lymphoma, nonHodgkin's lymphoma, hepatocytes cancer, gastrointestinal stromal tumor (
- Ring A is heteroaryl
- Ring A is indolyl, indazolyl, pyrro pyrrolo[2,3-c]pyridinyl, pyrro pyrrolo[3,2-c]pyridinyl, pyrro pyrrolo[2,3-b]pyridinyl, pyrro pyrrolo[3,2-b]pyridinyl, pyrro pyrrolo[2,3-b]pyrazinyl, indolin-2-onyl, pyridinyl, pyrazolyl or pyrimidinyl.
- R 1 is hydrogen, halogen or haloC 1 -C 4 alkyl.
- R 1 is hydrogen, chloro, fluoro or trifluoromethyl.
- R 2 is C 1 -C 4 alkyl or haloC 1 -C 4 alkyl, preferably C 2 -C 4 alkyl or haloC 2 -C 4 alkyl, more preferably isopropyl or trifluoroethyl.
- R 4 is
- R 7 and R 7 ′ are each independently hydrogen or C 1 -C 4 alkyl.
- R 4 is
- R 7 is hydrogen
- R 3 is selected from a group consisting of
- halogen —CN, —NO 2 , C 1 -C 4 alkyl, haloC 1 -C 4 alkyl, —C(O)R 7 , —C(O)NR 7 R 7 ′, —OR 7 , —NHR 7 , —NR 7 —(C 1 -C 4 alkyl), —NR 7 (CH 2 ) n C(O)R 6 or —NR 6 R 7 ,
- heterocycloalkyl that is unsubstituted or substituted with 1-3 substituents selected from halogen, C 1 -C 4 alkyl, haloC 1 -C 4 alkyl, —(CH 2 ) n OH, —NR 7 R 7 ′, —OR 7 or —C(O)R 7 ;
- R 6 is —(CH 2 ) q OR 7 , —(CH 2 ) q NR 7 R 7 ′, —(CH 2 ) q C(O)R 7 or —(CH 2 ) q C(O)NR 7 R 7 ′;
- R 7 and R 7 ′ are each independently hydrogen, C 1 -C 4 alkyl or haloC 1 -C 4 alkyl, or R 7 , R 7 ′ and the nitrogen atom attached thereto are cyclized together to form a heterocycloalkyl;
- n 0, 1, 2, 3 or 4;
- q 0, 1, 2, 3 or 4.
- R 3 is —NR 6 R 7 , wherein R 6 is —(CH 2 ) q NR 7 R 7 ′, R 7 and R 7 ′ are each independently hydrogen or C 1 -C 4 alkyl, q is 2.
- R 3 is a heterocycloalkyl substituted by one substituent selected from halogen, C 1 -C 4 alkyl, haloC 1 -C 4 alkyl or —NR 7 R 7 ′, R 7 and R 7 ′ are each independently hydrogen or C 1 -C 4 alkyl; more preferably, the heterocycloalkyl is pyrrolidinyl.
- each R 5 is dependently independently halogen, C 1 -C 4 alkyl, haloC 1 -C 4 alkyl, —OR 7 , —NR 7 R 7 ′, —CN or —NO 2 , R 7 and R 7 ′ are each independently hydrogen or C 1 -C 4 alkyl, m is 1, 2 or 3.
- each R 5 is dependently independently halogen, C 1 -C 4 alkyl, —OR 7 or —NR 7 R 7 ′, R 7 and R 7 ′ are each independently hydrogen or C 1 -C 4 alkyl, m is 1, 2 or 3.
- the specifically preferable compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof according to the present invention includes:
- the present invention also provides a process for preparing the compound represented by the general formula (I), which comprises the steps of:
- L represents a leaving group, including hydrogen, halogen or
- compounds (a) and (b) are used as starting material, and subjected to substitution under a catalyst to produce an Intermediate 2; the Intermediate 2 and an Intermediate 1 are subjected to substitution or coupling reaction to produce a compound (c), the nitro group of the compound (c) is reduced to produce a compound (d), the compound (d) is acylated to produce a compound (I); or the Intermediate 2 and an Intermediate 1′ are subjected to substitution or coupling reaction to directly produce a compound (I).
- the catalyst for carrying out the substitution reaction of the compounds (a) and (b) includes a Lewis acid such as AlCl 3 or a transition metal catalyst such as bis (pinacolato)diboron/PdCl 2 (dppf), PdCl 2 (dppf); the substitution or coupling reaction of Intermediate 2 and Intermediate 1 can also be carried out under the catalysis of a transition metal catalyst including but not limited to Pd2(dba)3/xantphos; conventional reducing agents well known in the art are used in the reduction of the nitro group, includes but is not limited to iron powders, zinc powders, sodium sulfide, H 2 /PtO 2 ; the acylation of the compound (d) is carried out with the corresponding acyl halide such as acyl chloride.
- a Lewis acid such as AlCl 3
- a transition metal catalyst such as bis (pinacolato)diboron/PdCl 2 (dppf), PdCl 2 (dppf)
- the preparation process for Intermediate 1 and Intermediate 1′ comprises the steps of,
- R 2 , R 3 and R 4 are defined as in the above general formula (I); 2,6-dichloro-3-nitropyridine is used as starting material, and subjected to etherification to produce a compound (e), the nitro group of the compound (e) is reduced to produce a compound (f), the compound (f) is then subjected to a reaction to produce a compound (g), the compound (g) is subjected to nitration to produce a compound (h), the compound (h) and R 3 H are subjected to substitution to produce a compound (i), and the compound (i) is then deprotected to produce the Intermediate 1; the compound (i) is subjected to Boc-protection to produce a compound (j), the compound (j) is then subjected to acetyl-deprotection to produce a compound (k), the nitro group of the compound (k) is reduced to produce a compound (l), the compound (l) is subjected to acylation to produce a compound (m),
- the etherification reaction is carried out in presence of a strong base which includes, but is not limited to sodium hydride, potassium hydride, sodium hydroxide, potassium hydroxide, sodium ethoxide, and sodium methoxide; conventional reducing agents well known in the art are used in the reduction of the nitro group, includes but is not limited to iron powders, zinc powders, sodium sulfide, H 2 /PtO 2 ; protection and deprotection are the conventional method well known in the art, and are carried out in an appropriate acidic or basic condition.
- a strong base which includes, but is not limited to sodium hydride, potassium hydride, sodium hydroxide, potassium hydroxide, sodium ethoxide, and sodium methoxide
- conventional reducing agents well known in the art are used in the reduction of the nitro group, includes but is not limited to iron powders, zinc powders, sodium sulfide, H 2 /PtO 2
- protection and deprotection are the conventional method well known in the art, and
- halogen means fluoro, chloro, bromo iodo and the like, preferably fluoro, chloro and bromo, and more preferably chloro.
- C 1 -C 4 alkyl means methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl or tert-butyl
- C 2 -C 4 alkyl means ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl or tert-butyl, preferably ethyl, propyl, isopropyl or butyl, more preferably isopropyl.
- haloC 1 -C 4 alkyl means the C 1 -C 4 alkyl, as defined herein, which is substituted with one or more halogen atoms, preferably 1-5 halogen atoms, including but not limited to, trifluoromethyl, trifluoroethyl, difluoromethyl, 1-chloro-2-fluoroethyl and the like.
- haloC 2 -C 4 alkyl includes but is not limited to trifluoroethyl, difluoromethyl, 1-chloro-2-fluoroethyl and the like, preferably trifluoroethyl.
- alkenyl means a mono-valent group derived from a hydrocarbon group
- C 2 -C 6 alkenyl means an alkenyl group containing 2 to 6 carbon atoms and at least containing one C—C double bond, including but not limited to, ethenyl, propenyl, butenyl, 2-methyl-2-butenyl, 2-methyl-2-pentenyl and the like.
- alkynyl means a mono-valent group derived from a hydrocarbon group
- C 2 -C 6 alkynyl means an alkynyl group containing 2 to 6 carbon atoms and at least containing one C—C triple bond, including but not limited to, ethynyl, propynyl, 1-butynyl, 2-butynyl and the like.
- cycloalkyl means a mono-valent group derived from monocyclic or polycyclic, saturated or partially unsaturated aliphatic carbocyclic compounds
- C 3 -C 8 -cycloalkyl includes but is not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclooctenyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl
- C 9 -C 12 - includes but is not limited to bicyclo[2.2.1]heptyl, bicyclo[2.2.1]octyl and the like.
- heterocycloalkyl means a monovalent monocyclic group, which is saturated or partially unsaturated (but not aromatic) and contains 3-8 ring members, preferably 4-7 ring members, or a monovalent fused bicyclic group, which is saturated or partially unsaturated (but not aromatic) and contains 5-12 ring members, preferably 7-10 ring members, wherein 1-4 ring heteroatom(s) is/are selected from a group consisting of O, S and N, and the remaining ring atoms are carbon.
- Said heterocycloalkyl includes but is not limited to azetidinyl, oxetanyl, pyrrolidinyl, piperidyl, morpholinyl, piperazinyl, tetrahydropyranyl, pyrazolidinyl, pyrazolinyl, imidazolinyl, imidazolidinyl, [1,3]dioxolane (dioxolane), dihydropyridinyl, tetrahydropyridinyl, hexahydropyridinyl, oxazolinyl, oxazolidinyl, iso-oxazolidinyl, thiazolinyl, thiazolidinyl, tetrahydrothiazolyl, iso-tetrahydrothiazolyl, octahydroindolyl, octahydroisoindolyl, tetrahydrofuryl
- aryl means an aromatic cyclic hydrocarbyl, which is a fused or non-fused carbonaceous ring system containing one or more aromatic rings, and includes but is not limited to phenyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl and the like, preferably an aryl containing 6-14 carbon atoms, more preferably an to aryl containing 6-10 carbon atoms, such as phenyl and naphthyl, more preferably phenyl.
- heteroaryl means 5-6 membered monocyclic heteroaryl containing 1-4 heteroatoms selected from N, S or O, or bicyclic heteroaryl formed is by fusing said 5-6 membered monocyclic heteroaryl with a benzene ring, pyridine ring or pyrrole ring, said heteroaryl can be partially saturated.
- Said heteroaryl includes but is not limited to furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, benzofuranyl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzimidazolyl, indolyl, isoindolyl, indazolyl, quinolyl, isoquinolyl, quinazolinyl, 1,2,3,4-tetrahydroisoquinolyl, pyrro pyrrolo[2,3-c]pyridinyl, pyrro pyrrolo[3,2-c]pyridinyl, pyrro pyrrolo[
- the present invention also includes the pharmaceutically acceptable salt of the compound represented by formula (I).
- pharmaceutically acceptable salt means relatively nontoxic acid addition salts or base addition salts of the compound of the present invention.
- Said acid addition salts are the salts formed between the compound represented by formula (I) of the present invention and suitable inorganic acids or organic acids. Said salts may be prepared during the final separation and purification processes of the compounds, or may be prepared through the reaction of purified compound represented by formula (I) in the form of free base thereof and suitable organic acids or inorganic acids.
- Representative acid addition salts includes hydrobromic acid salt, hydrochloric acid salt, sulfate, bisulfate, sulfite, acetate, oxalate, valerate, oleate, palmate, stearate, laurate, borate, benzoate, lactate, phosphate, hydrogen phosphate, carbonate, bicarbonate, toluate, citrate, maleate, fumarate, succinate, tartrate, benzoate, mesylate, p-tosylate, glyconate, lactobionate and laurylsulfonate and the like.
- Said base addition salts are the salts formed between the compound represented by formula (I) and suitable inorganic bases or organic bases, including such as the salts formed with alkali metals, alkaline earth metals, quaternary ammonium cations, such as sodium salts, lithium salts, potassium salts, calcium salts, magnesium salts, tetramethylammonium salts, tetraethylammonium salt and the like; amine salts, including the salts formed with ammonia (NH 3 ), primary amines, secondary amines or tertiary amines, such as: methylamine salts, dimethylamine salts, trimethylamine salts, triethylamine salts, ethylamine salts and the like.
- suitable inorganic bases or organic bases including such as the salts formed with alkali metals, alkaline earth metals, quaternary ammonium cations, such as sodium salts, lithium salts, potassium salts, calcium salts, magnesium salts
- the compound of the present invention or a pharmaceutically acceptable salt thereof can be administered to mammals, such as human, and administrated orally, rectally,parenterally (intravenously, intramuscularly or subcutaneously), topically (such as in the form of powders, ointments or drops), or intratumorally.
- the administration dosage of the compound of the present invention can be about 0.05-50 mg/kg body weight/day, e.g. 0.1-45 mg/kg body weight/day, 0.5-35 mg/kg body weight/day.
- the compound of the present invention or a pharmaceutically acceptable salt thereof can be formulated into the solid dosage fonns for oral administration, which includes but is not limited to capsules, tablets, pills, powders and granules and the like.
- the compounds represented by formula (I) of the present invention as active ingredients are admixed with at least one conventional inert excipients (or carriers), such as sodium citrate or dicalcium phosphate, or admixed with the following ingredients: (1) fillers or extenders, such as, starch, lactose, sucrose, glucose, mannitol and silicic acid and the like; (2) adhesives, such as, hydroxymethylcellulose, alginate, gelatin, polyvinyl pyrrolidine, sucrose and acacia and the like; (3) humectants, such as, glycerol and the like; (4) disintegrating agents, such as, agar, calcium carbonate, potato starch or tapioca, alginic acid, certain composite si
- Said solid dosage forms such as tablets, sugar pills, capsules, pills and granules can also by coated or microencapsulated by coatings and shell materials such as enteric coatings and other materials well known in the art. They may comprise opacifying agents, and the release of active ingredients in these compositions may be carried out in a certain portion of digestive tube in a retarded manner.
- coatings and shell materials such as enteric coatings and other materials well known in the art. They may comprise opacifying agents, and the release of active ingredients in these compositions may be carried out in a certain portion of digestive tube in a retarded manner.
- the examples for embedding components that may be adopted are polymers and waxes. If necessary, active ingredients can also be formulated into the form of microcapsules with one or more of the above excipients.
- the compound of the present invention or a pharmaceutically acceptable salt thereof can be formulated into liquid dosage forms for oral administration, including but not limited to pharmaceutically acceptable emulsions, solutions, suspensions, syrups and tinctures and the like.
- the liquid dosage forms may comprise inert diluents customarily used in the art, such as water and other solvents, solubilizers and emulsifiers, such as, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethyl formamide, and oils, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil and the like or mixtures of these materials and the like.
- the liquid dosage forms of the present invention may also comprise conventional auxiliaries, such as moistening agents, emulsifiers
- Said suspending agents includes, such as, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan ester, microcrystalline cellulose, aluminium methoxide and agar and the like or mixtures of these materials.
- the compound of the present invention or a pharmaceutically acceptable salt thereof can be formulated into dosage forms for parenteral injection, including but not limited to physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powder for re-dissolving into sterile injectable solutions or dispersions.
- Suitable carriers, diluents, solvents or excipients include water, ethanol, polyhydric alcohol and suitable mixtures thereof.
- the compound of the present invention or a pharmaceutically acceptable salt thereof can also be formulated into dosage forms for topical administration, including but not limited to ointments, powders, suppositories, drops, propellants and inhalants and the like.
- the compounds represented by formula (I) of the present invention or a pharmaceutically acceptable salt thereof as active ingredients are admixed together with physiologically acceptable carriers and optional preservatives, buffers, or if necessary, propellants, under sterile condition.
- the present invention also provides a pharmaceutical composition containing the compound represented by formula (I) of the present invention or a pharmaceutically acceptable salt thereof as active ingredients, and pharmaceutically acceptable carriers, excipients or diluents.
- the compound represented by formula (I) of the present invention or a pharmaceutically acceptable salt thereof is generally admixed with pharmaceutically acceptable carriers, excipients or diluents.
- the content of the compound of the general formula (I) or a pharmaceutically acceptable salt thereof can be 0.01-1000 mg, for example 0.05-800 mg, 0.1-500 mg, 0.01-300 mg, 0.01-200 mg, 0.05-150 mg, 0.05-50 mg and the like.
- composition of the present invention may be formulated into conventional pharmaceutical preparations, such as tablets, pills, capsules, powder, granules, emulsions, suspensions, dispersions, solutions, syrups, elixirs, ointments, drops, suppositories, inhalants, propellants and the like.
- the compound of the present invention or a pharmaceutically acceptable salt thereof may be administered alone or in combination with other pharmaceutically acceptable therapeutic agents, especially with other anti-tumor drugs.
- the therapeutic agents include but are not limited to anti-tumor drugs which exert an influence on the chemical structure of DNA, such as Cisplatin, anti-tumor drugs which affect the synthesis of nucleic acid, such as Methotrexate (MTX), 5-Fluorouracil (5FU) and the like, anti-tumor drugs which affect the transcription of nucleic acid, such as Adriamycin, Epirubicin, Aclacinomycin, Mitramycin and the like, anti-tumor drugs which exert an influence on synthesis of tubulin, such as Paclitaxel, Vinorelbine and the like, aromatase inhibitors such as Aminoglutethimide, Lentaron, Letrozole, Anastrozole and the like, inhibitors of the cell signal pathway such as epidermal growth factor receptor inhibitors Imatinib, Gefitinib
- Each therapeutic agent to be combined can be administered simultaneously or sequentially, and can be administered either in a unitary formulation or in separate formulations.
- Such combination includes not only the combination of the compound of the present invention with another active ingredient but also the combination of the compound of the present invention with two or more other active ingredients.
- the compound of the present invention has a good proliferation inhibition effect on the activating mutation or resistant mutation tumor cells and a weak proliferation inhibition effect on the wild-type EGFR cancer cells, and has a good selectivity.
- the compound of the present invention can be used as the medicament for treating a disease or condition mediated by the activity of EGFR activating or resistant mutation, in particular tumor, e.g. cancer.
- Said cancer includes but is not limited to, e.g.
- lung cancer ovarian cancer, cervical cancer, breast cancer, stomach cancer, colorectal cancer, pancreatic cancer, glioma, glioblastoma, melanoma, prostate cancer, leukemia, lymphoma, nonHodgkin's lymphoma, hepatocytes cancer, gastrointestinal stromal tumor (GIST), thyroid cancer, cholangiocarcinoma, endometrial cancer, renal cancer, anaplastic large cell lymphoma, acute myeloid leukemia (AML), multiple myeloma, mesothelioma, in particular a type of tumor wherein threonine at position 790 of the epidermal growth factor receptor is mutated into methionine (EGFR T790M).
- GIST gastrointestinal stromal tumor
- AML acute myeloid leukemia
- mesothelioma in particular a type of tumor wherein threonine at position 790 of the epidermal growth factor receptor is mutated into methi
- the compound of the present invention can be used as medicament for treating the non-small cell cancer (EGFR T790M). It can be used to overcome the resistency problem caused by EGFR T790M after Gefitinib and Erlotinib are clinically used. Due to the reduced toxicity associated with the inhibition of the wild-type EGFR, it is therefore expected that the compound of the present invention will produce a relatively small toxic and side-effect upon being applied to the cancer treatment.
- EGFR T790M non-small cell cancer
- the pharmacodynamic action of the compound of the present invention in terms of inhibiting the proliferation of cancer cells may be assayed by conventional methods.
- One preferable evaluation method of which is Sulforhodamine B (SRB) protein staining method, which calculates the inhibition ratio of a drug against the proliferation of cancer cells by measuring the change in optical absorption value generated after the drug has acted on the cancer cells.
- Inhibition ratio (%) [(blank control OD-inhibitor OD)/blank control OD] ⁇ 100%
- Blank control OD the OD value of the well of normally growed cells without the action of a drug.
- Inhibitor OD the OD value of the well of cells with the action of the added compounds to be screened.
- the median inhibitory concentration (IC 50 ) value is obtained by the software GraphPad Prism 5.0 by the 4-parameter logistic curve fit calculation. Each experiment is repeated three times, and the average IC 50 value for three experiments is used as the final index for the inhibitory ability.
- the pharmacodynamic action of the compound of the present invention in terms of inhibiting the growth of transplanted tumors in animal may be assayed by conventional methods.
- One preferable evaluation method of which is the inhibitory effect on the growth of subcutaneously transplanted tumors of human lung cancer H1975-bearing nude mice.
- the experimental method is as follows: human lung cancer H1975 cell strain (5 ⁇ 10 6 /each mouse) is inoculated to nude mice subcutaneously at the right side of the back thereof. After the tumors grow to 100-150 mm 3 on average, the animals are divided into groups randomly according to the tumor size and the animal weight.
- test compounds are administered by intragastric administration in a certain dosages, and solvent control groups are administered with equal amount of solvent by intragastric administration, wherein the administration is performed once per day for a continuous period of 12 days.
- the animal weight and the tumor size are measured twice per week, so as to observe whether or not the toxic reaction occurs.
- FIG. 1 is the tumor volume curve for subcutaneously transplanted tumors of human lung cancer H1975-bearing nude mice at the administration dosage of 25 mg/kg of the compound of Example 3 and AZD9291.
- FIG. 2 is the body weight curve for human lung cancer H1975-bearing nude mice at the administration dosage of 25 mg/kg of the compound of Example 3 and AZD9291.
- 6-chloro-2-methoxypyridin-3-amine 1.6 g, 10.1 mmol
- diisopropylethylamine 2.6 ml, 15.1 mmol
- dichloromethane 100 ml dichloromethane.
- the mixture was cooled to 5° C. in an ice bath.
- Acetyl chloride (0.86 ml, 12.1 mmol) was added. The reaction continued for 1.25 hours.
- Step 5 Synthesis of N- ⁇ 6- ⁇ [2-(dimethylamino)ethyl](methyl)amino ⁇ -2-methoxy-5-nitropyridin-3-yl ⁇ acetamide hydrochloride
- N-(6-chloro-2-methoxy-5-nitropyridin-3-yl)acetamide 1.0 g, 4.1 mmol
- 30 ml acetonitrile 30 ml acetonitrile
- N,N,N′-trimethylethylenediamine 0.6 g, 6.1 mmol
- the reaction mixture was reacted at 80° C. for 3 hours.
- the reaction mixture was concentrated under a reduced pressure to about 1 ⁇ 3 of the original volume.
- 50 ml ethyl acetate was added.
- the mixture was stirred for several minutes, a solid precipitated and was filtered to produce 1.1 g of an beige solid with a yield of 87%.
- Step 6 Synthesis of N 2 -methyl-N 2 -[2-(dimethylamino)ethyl]-6-methoxy-3-nitropyridin-2,5-diamine hydrochloride
- Step 5 Synthesis of N- ⁇ 6- ⁇ [2-(dimethylamino)ethyl](methyl)amino ⁇ -2-isopropyloxy-5-nitropyridin-3-yl ⁇ acetamide
- N-(6-chloro-2-isopropyloxy-5-nitropyridin-3-yl)acetamide 15 g, 54.8 mmol
- 150 ml acetonitrile 150 ml acetonitrile
- N,N,N′-trimethylethylenediamine 7.28 g, 71.3 mmol
- potassium carbonate 15.15 g, 110 mmol
- Step 6 Synthesis of N 2 -methyl-N 2 -[2-(dimethylamino)ethyl]-6-isopropyloxy-3-nitropyridin-2,5-diamine
- Step 5 Synthesis of N- ⁇ 6- ⁇ [2-(dimethylamino)ethyl](methyl)amino ⁇ -2-(2,2,2-trifluoroethoxyl)-5-nitropyridin-3-yl ⁇ acetamide
- N-[6-chloro-2-(2,2,2-trifluoroethoxyl)]-5-nitropyridin-3-ypacetamide (626 mg, 2 mmol)
- 10 ml acetonitrile 10 ml acetonitrile
- N,N,N′-trimethylethylenediamine 224 mg, 2.2 mmol
- potassium carbonate 138 mg, 4 mmol
- Step 6 Synthesis of N 2 -methyl-N 2 -[2-(dimethylamino)ethyl]-6-(2,2,2-trifluoroethoxyl)-3-nitropyridin-2,5-diamine
- Step 1 Synthesis of N-tert-butoxycarbonyl-N- ⁇ 6- ⁇ [2-(dimethylamino)ethyl](methyl)amino ⁇ -2-isopropyloxy-5-nitropyridin-3-yl ⁇ acetamide
- Step 2 Synthesis of tert-butyl ⁇ 6-( ⁇ [2-(dimethylamino)ethyl](methyl)amino ⁇ -2-isopropyloxy-5-nitropyridin-3-yl ⁇ carbamate
- Step 3 Synthesis of tert-butyl ⁇ 5-amino-6- ⁇ [2-(dimethylamino)ethyl](methyl)amino ⁇ -2-isopropyloxypyridin-3-yl ⁇ carbamate
- Step 4 Synthesis of tert-butyl ⁇ 5-acrylamide-6- ⁇ [2-(dimethylamino)ethyl](methyl)amino ⁇ -2-isopropyloxypyridin-3-yl ⁇ -carbamate
- Step 2 Synthesis of tert-butyl ⁇ 6- f[2-(dimethylamino)ethyl](methypamino ⁇ -2-(2,2,2-trifluoroethoxyl)-5-nitropyridin-3-ylIcarbamate
- Step 3 Synthesis of tert-butyl ⁇ 5-amino-6- ⁇ [2-(dimethylamino)ethyl](methyl)amino ⁇ -2-(2,2,2-trifluoroethoxyl)pyridin-3-yl ⁇ carbamate
- Step 4 Synthesis of tert-butyl ⁇ 5-acrylamide-6- ⁇ [2-(dimethylamino)ethyl](methyl 0 amino ⁇ -2-(2,2,2-trifluoroethoxyl)pyridin-3-yl ⁇ carbamate
- Step 2 Synthesis of 3-(2,5-dichloropyrimidin-4-yl)-1-p-tosyl-1H-pyrropyrrolo[2,3-b]pyridine
- Step 1 Synthesis of N 2 -methyl-N 2 -[2-(dimethylamino)ethyl]-6-isopropyloxy-N 5 [5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]-3-nitropyridin-2,5-diamine
- N 2 -methyl-N 2 -[2-(dimethylamino)ethyl]-6-isopropyloxy-3-nitropyridin-2,5-diamine (490 mg, 1.65 mmol)
- 3-(2,5-dichloropyrimidin-4-yl)-1-methyl-1H-indole 550 mg, 1.98 mmol
- tris(dibenzylideneacetone)dipalladium (226 mg, 0.2475 mmol
- 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene (286 mg, 0.495 mmol)
- potassium phosphate (874 mg, 4.125 mmol) and 15 ml dioxane.
- Step 2 Synthesis of N 2 -methyl-N 2 -[2-(dimethylamino)ethyl]-6-isopropyloxy-N 5 -[5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]pyridin-2,3,5-triamine
- a reduced iron powders 240 mg, 4.26 mmol. The mixture was stirred at 80° C. for 1 hour.
- Step 3 Synthesis of N- ⁇ 2- ⁇ [2-(dimethylamino)ethyl](methyl)amino ⁇ -6-isopropyloxy-5- ⁇ 5-chloro-[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino ⁇ pyridin-3-yl ⁇ acrylamide
- N 2 -methyl-N 2 -[2-(dimethylamino)ethyl]-6-isopropyloxy-N 5 -[5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]pyridin-2,3,5-triamine 196 mg, 0.385 mmol
- the reaction mixture was cooled in an ice-water bath.
- 0.5 N of a solution of acryloyl chloride in dichloromethane (0.8 ml, 0.4 mmol) and triethylamine (0.15 ml, 1.08 mmol) were added.
- Step 1 Synthesis of N 2 -methyl-N 2 -[2-(dimethylamino)ethyl]-6-isopropyloxy-N 5 -[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]-3-nitropyridin-2,5-diamine
- the compound was synthesized in the same manner as those in Step 1 of Example 1 with a yield of 100%.
- Step 2 Synthesis of N 2 -methyl-N 2 -[2-(dimethylamino)ethyl]-6-isopropylory-N 5 -[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]pyridin-2,3,5-triamine
- N 2 -methyl-N 2 -[2(dimethylamino)ethyl]-6-isopropyloxy-N 5 -[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]-3-nitropyridin-2,5-diamine 200 mg, 0.397 mmol was dissolved in 12 ml methanol. 35 mg platinum dioxide was added and hydrogen was introduced. The resulting mixture was stirred at room temperature for 1.5 hour, and filtered.
- Step 3 Synthesis of N- ⁇ 2- ⁇ [2-(dimethylamino)ethyl](methyl)amino ⁇ -6-isopropyloxy-5- ⁇ [4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino ⁇ pyridin-3-yl ⁇ acrylamide
- Step 1 Synthesis of N 2 -methyl-N 2 -[2-(dimethylamino)ethyl]-6-(2,2,2-trifluoroethoxyl)-N 5 -[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]-3-nitropyridin-2,5-diamine
- Step 2 Synthesis of N 2 -methyl-N 2 -[2-(dimethylamino)ethyl]-6-(2,2,2-trifluoroethoxyl)-N 5 -[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]pyridin-2,3,5-triamine
- Step 3 Synthesis of N- ⁇ 2- ⁇ [2-(dimethylamino)ethyl](methyl)amino ⁇ -6-(2,2,2-trifluoroethoxyl)-5- ⁇ [4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino ⁇ pyridin-3-yl ⁇ acrylamide
- Step 1 Synthesis of N 2 -methyl-N 2 -[2-(dimethylamino)ethyl]-6-(2,2,2-trifluoroethoxyl)-N 5 -[5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]-3-nitropyridin-2,5-diamine
- the compound was synthesized in the same manner as those in Step 1 of Example 1 with a yield of 86%.
- Step 2 Synthesis of N 2 -methyl-N 2 -[2-(dimethylamino)ethyl]-6-(2,2,2-trifluoroethoxyl)-N 5 -[5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]pyridin-2,3,5-triamine
- Step 3 Synthesis of N- ⁇ 2- ⁇ [2-(dimethylamino)ethyl](methyl)amino ⁇ -6-(2,2,2-trifluoroethoxyl)-5- ⁇ 5-chloro-[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino ⁇ pyridin-3-yl ⁇ acrylamide
- Step 1 Synthesis of N 2 -methyl-N 2 -[2(dimethylamino)ethyl]-6-isopropyloxy-N 5 -[4-(1-methyl-5-fluoro-1H-indol-3-yl)pyrimidin-2-yl]-3-nitropyridin-2,5-diamine
- Step 2 Synthesis of N 2 -methyl-N 2 -[2(dimethylamino)ethyl]-6-isopropyloxy-N 5 -[4-(1-methyl-5-fluoro-1H-indol-3-yl)pyrimidin-2-yl]pyridin-2,3,5-triamine
- Step 3 Synthesis of N- ⁇ 2- ⁇ [2-(dimethylamino)ethyl](methy)amino ⁇ -6-isopropyloxy-5- ⁇ [4-(1-methyl-5-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amino ⁇ pyridin-3-yl ⁇ acrylamide
- Step 1 Synthesis of N 2 -methyl-N 2 -[2-(dimethylamino)ethyl]-6-isopropyloxy-N 5 -[4-(1-methyl-5,6-difluoro-1H-indol-3-yl)pyrimidin-2-yl]-3-nitropyridin-2,5-diamine
- Step 2 Synthesis of N 2 -methyl-N 2 -[2-(dimethylamino)ethyl]-6-isopropyloxy-N 5 -[4-(1-methyl-5,6-difluoro-1H-indol-3-yl)pyrimidin-2-yl]pyridin-2,3,5-triamine
- Step 3 Synthesis of N- ⁇ 2- ⁇ [2-(dimethylamino)ethyl](methyl)amino ⁇ -6-isopropyloxy-5- ⁇ [4-(1-methyl-5,6-difluoro-1H-indol-3-yl)pyrimidin-2-yl]amino ⁇ pyridin-3 -yl ⁇ acrylamide
- Example 8 N- ⁇ 2- ⁇ [2-(dimethylamino)ethyl](methyl)amino ⁇ -6-isopropyloxy-5- ⁇ 5-chloro-[4-(1-methyl-5,6-difluoro-1H-indol-3-yl)pyrimidin-2-yl]amino ⁇ pyridin-3-yl ⁇ acrylamide
- Example 17 N- ⁇ 2- ⁇ [2-(dimethylamino)ethyl](methyl)amino ⁇ -6-isopropyloxy-5- ⁇ 5-chloro-[4-(1-methyl-5,6-difluoro-1H-indol-3-yl)pyrimidin-2-yl]amino ⁇ pyridin-3-yl ⁇ acrylamide methanesulfonate
- the compound was synthesized in the substantially same manner as those in Example 16. Ethyl acetate was added to the final crude product. The mixture was ultrasonically treated and filtered to produce a product with a yield of 43%.
- the compound was synthesized in the substantially same manner as those in Example 16. Ethyl acetate was added to the final crude product. The mixture was ultrasonically treated and filtered to produce a product with a yield of 96%.
- Step 1 Synthesis of N 2 -methyl-N 2 -[2-(dimethylamino)ethyl]-6-isopropyloxy-N 5 -[5-chloro-4-(1-methyl-1H-pyrropyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl]-3-nitropyridin-2,5-diamine
- Step 2 Synthesis of N 2 -methyl-N 2 -[2-(dimethylamino)ethyl]-6-isopropyloxy-N 5 -[5-chloro-4-(1-methyl-1H-pyrropyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl]pyridin-2,3,5-triamine
- Step 3 Synthesis of N- ⁇ 2- ⁇ [2-(dimethylamino)ethyl](methyl)amino ⁇ -6-isopropyloxy-5- ⁇ [5-chloro-4-(1-methyl-1H-pyrropyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl]amino ⁇ pyridin-3-yl ⁇ acrylamide
- Cells in the logarithmic phase were inoculated to 96-well culture plates (cell density: 5000/well, cell suspension: 180 ⁇ l/well), and cultured at 37° C. under 5% CO 2 for 24 hours. After the culturing, the cells adhered to the well walls.
- Each of compounds was dissolved in DMSO in advance to formulate a 10 nM stock solution. Upon testing, the stock solution was diluted with complete medium to 10 times the target concentration in another 96-cell plate. And then the compound was added at 20 ⁇ l/cell in the 96-well plate in which the cells were inoculated, i.e. the target concentration could be reached. The well for each concentration was triplicated, and the blank control was established.
- Cells continued to be cultured at 37° C. under 5% CO 2 for 72 hours. After the termination of culturing, 50 ⁇ l pre-cooled (4° C.) 50% trichloroacetic acid, i.e., TCA was added to each of wells (final concentration 10%), and was placed at 4° C. for 1 hour to fix the cells. The resulting matter was washed with purified water for at least 5 times, and dried naturally in air or at 60° C. in an oven. 4 mg/ml Sulforhodamine B (SRB) solution prepared by 1% glacial acetic acid/purified water was added at 100 ⁇ l/well to each well so as to stain for 1 hour at room temperature. The supernatant was discarded.
- SRB Sulforhodamine B
- the test results showed that the compounds of the present invention had a strong proliferation inhibition effect on human lung cancer cell (HCC827, EGFR Exon 19 deletion activating mutation) and human lung cancer cell (H1975, EGFR L858R/T790M resistant mutation), a relatively weak proliferation inhibition effect on human skin cancer cell (A431, wild-type EGFR), that is to say, the compounds of the present invention had a good selectivity.
- H1975 was placed in a RPMI-1640 medium containing 10% FBS, and cultivated in a temperature-constant incubator containing 5% CO 2 at 37° C. The cells in exponential growth phase were collected and counted for inoculation.
- Test animals 15 BALB/c nude mices, 15 males and 0 female, 6 weeks old, 18-20 g, commercially available from Shanghai Lab. Animal Research Center
- test groups were established: 0.5% sodium carboxymethylcellucose solvent control group, the groups of the compound of Example 3 at 25 mg/kg and the groups of AZD9291 at 25 mg/kg, respectively.
- mice human lung cancer H1975 cell strain (5 ⁇ 10 6 /each mouse) was inoculated to nude mice subcutaneously at the right side of the back thereof. Each mouse was inoculated with 0.1 ml, and the tumor growth was observed regularly. After the tumors grew to 100-150 mm 3 on average, the mice were divided into groups randomly according to the tumor size and the mouse weight.
- the compound of Example 3 and AZD9291 were administered by intragastric administration in the dosage of 25 mg/kg, and solvent control groups were administered with equal amount of solvent by intragastric administration, wherein the administration was performed once per day for a continuous period of 12 days. During the entire experimental process, the mouse weight and the tumor size were measured twice per week, so as to observe whether or not the toxic reaction occurs.
- the tumor growth curves of three experimental groups are shown in FIG. 1
- the mice's weight growth curves are shown in FIG. 2 .
- the results show that the compounds of the present invention have a good inhibition effect on the growth of subcutaneously transplanted tumors of human lung cancer H1975-bearing nude mice, while having little effect on the weights of nude mice, and showing a good safety.
Abstract
Description
wherein,
Ring A is aryl or heteroaryl;
R1 is selected from a group consisting of hydrogen, halogen, C1-C4alkyl, haloC1-C4-alkyl, C2-C6alkenyl, C2-C6alkynyl or —CN;
R2 is selected from a group consisting of C1-C4alkyl, haloC1-C4-alkyl, C2-C6alkenyl, —(CH2)qOR7, —(CH2)qNR7R7′ or —(CH2)qC(O)R7;
Each R5 is dependently independently halogen, C1-C4alkyl, haloC1-C4alkyl, C2-C6alkenyl, C2-C6alkynyl, —OR6, —C(O)R7, —C(O)NR7R7′, —OR7, —NR7R7′, —CN or —NO2;
R3 is selected from a group consisting of halogen, —CN, —NO2, C1-C4alkyl, haloC1-C4alkyl, —C(O)R6, —C(O)R7, —C(O)NR7R7′, —OR7, —OR6, —NHR7, —NR7-(C1-C4alkyl), —NR7-(haloC1-C4alkyl), —NR7(CH2)nC(O)R6, —NR6R7, —NR7-heterocycloalkyl, wherein said heterocycloalkyl is unsubstituted or substituted with 1-2 substituents selected from R7, or —NR7SO2R7, or heterocycloalkyl that is unsubstituted or substituted with 1-3 substituents selected from halogen, C1-C4alkyl, haloC1-C4alkyl, —(CH2)nOH, —NR7R7′, —OR7 or —C(O)R7;
wherein, R6 is —(CH2)OR7, —(CH2)qNR7R7′, —(CH2)qNR7C(O)R7, —(CH2)qC(O)R7 or —(CH2)qC(O)NR7R7′;
R7 and R7′ are each independently hydrogen, C1-C4alkyl, C2-C6alkenyl, C2-C6alkynyl or haloC1-C4alkyl, or R7, R7′ and the nitrogen atom attached thereto are cyclized together together to form a heterocycloalkyl that is unsubstituted or substituted with 1-3 substituents selected from halogen, C1-C4alkyl, haloC1-C4alkyl, —(CH2)nOH, —NR7R7′, —OR7 or —C(O)R7;
m is 1, 2 or 3;
n is 0, 1, 2, 3 or 4;
q is 0, 1, 2, 3 or 4.
-
- N-{2-{[2-(dimethylamino)ethyl](methyl)amino}-6-isopropyloxy-5-{5-chloro-[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}pyridin-3-yl}acrylamide;
- N-{2-{[2-(dimethylamino)ethyl](methyl)amino}-6-isopropyloxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin2-yl]amino}pyridin-3-yl}acrylamide;
- N-{2-{[2-(dimethylamino)ethyl](methyl)amino}-6-(2,2,2-trifluoroethoxyl)-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}pyridin-3-yl}acrylamide;
- N-{2-{[2-(dimethylamino)ethyl](methyl)amino}-6-(2,2,2-trifluoroethoxyl)-5-{5-chloro-[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}pyridin-3-yl}acrylamide;
- N-{2-{[2-(dimethylamino)ethyl](methyl)amino}-6-isopropyloxy-5-{[4-(1-methyl-5-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amino}pyridin-3-yl}acrylamide;
- N-{2-{[2-(dimethylamino)ethyl](methyl)amino}-6-isopropyloxy-5-{[4-(1-methyl-5,6-difluoro-1H-indol-3-yl)pyrimidin-2-yl]amino}pyridin-3-yl}acrylamide;
- N-{2-{[2-(dimethylamino)ethyl](methyl)amino}-6-isopropyloxy-5-{5-chloro[4-(1-methyl-6-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amino}pyridin-3-yl}acrylamide;
- N-{2-{[2-(dimethylamino)ethyl](methyl)amino}-6-isopropyloxy-5-{5-chloro[4-(1-methyl-5,6-difluoro-1H-indol-3-yl)pyrimidin-2-yl]amino}pyridin-3-yl}acrylamide;
- N-{2-{[2-(dimethylamino)ethyl](methyl)amino}-6-isopropyloxy-5-{5-chloro-[4-(1-methyl-5-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amino}pyridin-3-yl}acrylamide;
- N-{2-{[2-(dimethylamino)ethyl](methyl)amino}-6-isopropyloxy-5-{5-fluoro-[4-(1-methyl-5-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amino}pyridin-3-yl}acrylamide;
- N-{2-{[2-(dimethylamino)ethyl](methyl)amino}-6-isopropyloxy-5-{5-fluoro-[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}pyridin-3-yl}acrylamide;
- N-{2-{[2-(dimethylamino)ethyl](methyl)amino}-6-isopropyloxy-5-{5-fluoro[4-(1-methyl-5,6-difluoro-1H-indol-3-yl)pyrimidin-2-yl]amino}pyridin-3-yl}acrylamide;
- N-{2-{[2-(dimethylamino)ethyl](methyl)amino}-6-isopropyloxy-5-{[4-(1-methyl-6-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amino}pyridin-3-yl}acrylamide;
- N-{2-{[2-(dimethylamino)ethyl](methyl)amino}-6-(2,2,2-trifluoroethoxyl)-5-{5-fluoro-[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}pyridin-3-yl}acrylamide;
- N-{2-{[2-(dimethylamino)ethyl](methyl)amino}-6-(2,2,2-trifluoroethoxyl)-5-{[4-(1-methyl-5-fluoro-1H-indol-3-yl)pyrimidin-2-yl]amino}pyridin-3-yl}acrylamide;
- N-{2-{[2-(dimethylamino)ethyl](methyl)amino}-6-isopropyloxy-5-{5-chloro-[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}pyridin-3-yl}acrylamide methanesulfonate;
- N-{2-{[2-(dimethylamino)ethyl](methyl)amino}-6-isopropyloxy-5-{5-chloro-[4-(1-methyl-5,6-difluoro-1H-indol-3-yl)pyrimidin-2-yl]amino}pyridin-3-yl}acrylamide methanesulfonate;
- N-{2-{[2-(dimethylamino)ethyl](methyl)amino}-6-isopropyloxy-5-{[4-(1-methyl-5,6-difluoro-1H-indol-3-yl)pyrimidin-2-yl]amino}pyridin-3-yl}acrylamide methanesulfonate;
- N-{2-{[2-(dimethylamino)ethyl](methyl)amino}-6-isopropyloxy-5-{[5-chloro-4-(1-methyl-1H-pyrropyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl]amino}pyridin-3-yl}acrylamide;
- N-{2-{[2-(dimethylamino)ethyl](methyl)amino}-6-isopropyloxy-5-{[5-chloro-4-(1-methyl-1H-pyrropyrrolo[2,3-b]pyridin-5-yl)pyrimidin-2-yl]amino}pyridin-3-yl}acrylamide;
- N-{2-{[2-(dimethylamino)ethyl](methyl)amino}-6-isopropyloxy-5-{[5-chloro-4-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-yl]amino}pyridin-3-yl}acrylamide;
- N-{2-{[2-(dimethylamino)ethyl](methy)amino}-6-isopropyloxy-5-{[5-chloro-2′-methoxy-(4,5′-bipyrimidine)-2-yl]amino}pyridin-3-yl}acrylamide; and
- N-{2-{[2-(dimethylamino)ethyl](methyl)amino}-6-isopropyloxy-5-{[5-chloro-2′amino-(4,5′-bipyrimidine)-2-yl]amino}pyridin-3-yl}acrylamide.
wherein ring A, R1, R2, R3, R4, R5, and m are identical to those defined in the above general formula (I); L represents a leaving group, including hydrogen, halogen or
compounds (a) and (b) are used as starting material, and subjected to substitution under a catalyst to produce an Intermediate 2; the Intermediate 2 and an Intermediate 1 are subjected to substitution or coupling reaction to produce a compound (c), the nitro group of the compound (c) is reduced to produce a compound (d), the compound (d) is acylated to produce a compound (I); or the Intermediate 2 and an Intermediate 1′ are subjected to substitution or coupling reaction to directly produce a compound (I).
wherein, R2, R3 and R4 are defined as in the above general formula (I); 2,6-dichloro-3-nitropyridine is used as starting material, and subjected to etherification to produce a compound (e), the nitro group of the compound (e) is reduced to produce a compound (f), the compound (f) is then subjected to a reaction to produce a compound (g), the compound (g) is subjected to nitration to produce a compound (h), the compound (h) and R3H are subjected to substitution to produce a compound (i), and the compound (i) is then deprotected to produce the Intermediate 1; the compound (i) is subjected to Boc-protection to produce a compound (j), the compound (j) is then subjected to acetyl-deprotection to produce a compound (k), the nitro group of the compound (k) is reduced to produce a compound (l), the compound (l) is subjected to acylation to produce a compound (m), and finally the compound (m) is subjected to Boc-deprotection to produce the Intermediate 1′.
AlCl3 | Aluminium chloride |
Bis(pinacolato)diboron | Bis(pinacolato)diboron |
PdCl2(dppf) | [1,1′-Bis(diphenylphosphino)ferrocene]dichloro- |
palladium | |
Pd2(dba)3 | Tris(dibenzylideneacetone)dipalladium |
Xantphos | 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene |
PtO2 | Platinum dioxide |
NaH | Sodium hydride |
THF | tetrahydrofuran |
p-TsCl | p-Toluenesulfonyl chloride |
KOAc | Potassium acetate |
Dioxane | Dioxane |
Na2CO3 | Sodium carbonate |
TBAF | Tetrabutylammonium fluoride |
MeI | Methyl iodide |
DMF | N,N-dimethylformamide |
Inhibition ratio (%)=[(blank control OD-inhibitor OD)/blank control OD]×100%
Tumor volume (mm3)=0.5×(Tumor major diameterx Tumor minor diameter2)
TABLE 1 | |||||
HCC827 | H1975 | A431 | |||
IC50 (nM) | IC50 (nM) | IC50 (nM) | |||
AZD9291 | 3.80 | 5.43 | 70.43 | ||
Example 1 compound | 2.15 | 5.64 | 140.5 | ||
Example 2 compound | 4.22 | 5.54 | 195.5 | ||
Example 3 compound | 1.34 | 2.28 | 224.2 | ||
Example 4 compound | 1.92 | 6.15 | 163.7 | ||
Example 5 compound | 2.58 | 4.83 | 181.4 | ||
Example 6 compound | 2.36 | 5.20 | 337.8 | ||
Example 7 compound | 1.40 | 16.68 | 307.0 | ||
Example 8 compound | 5.98 | 8.40 | 375.4 | ||
Example 9 compound | 1.17 | 12.58 | 697.2 | ||
Example 10 compound | 2.62 | 5.32 | 208.9 | ||
Example 11 compound | 2.23 | 7.22 | 210.3 | ||
Example 12 compound | 0.96 | 9.01 | 338.6 | ||
Example 13 compound | 2.62 | 5.33 | 208.9 | ||
Example 14 compound | 0.77 | 5.17 | 241.8 | ||
Example 15 compound | 0.69 | 6.28 | 337.4 | ||
Example 16 compound | 1.45 | 5.43 | 273.4 | ||
Example 17 compound | 5.56 | 7.63 | 375.4 | ||
Example 18 compound | 2.24 | 5.07 | 341.3 | ||
Example 19 compound | 2.62 | 2.56 | 208.9 | ||
Example 20 compound | 8.97 | 42.35 | 800.7 | ||
Example 21 compound | 142.4 | 18.55 | 369.8 | ||
Example 22 compound | 33.30 | 37.98 | 2765 | ||
Example 23 compound | 3.08 | 30.70 | 1145 | ||
Note: | |||||
AZD9291 was prepared according to Example 28 of WO 2013/014448 A1 |
Tumor volume (mm3)=0.5×(Tumor major diameterx Tumor minor diameter2)
Claims (25)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/376,987 USRE49851E1 (en) | 2014-07-29 | 2015-07-29 | Pyridinylaminopyrimidine derivatives, preparation process and use thereof |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410365911.4 | 2014-07-29 | ||
CN201410365911.4A CN105315259B (en) | 2014-07-29 | 2014-07-29 | Pyridine amine pyrimidine derivates, its preparation method and application |
US17/376,987 USRE49851E1 (en) | 2014-07-29 | 2015-07-29 | Pyridinylaminopyrimidine derivatives, preparation process and use thereof |
PCT/CN2015/000540 WO2016015453A1 (en) | 2014-07-29 | 2015-07-29 | Pyridine amidopyrimidine derivative, preparation method and use thereof |
US15/329,044 US10072002B2 (en) | 2014-07-29 | 2015-07-29 | Pyridinylaminopyrimidine derivatives, preparation process and use thereof |
US201916517790A | 2019-07-22 | 2019-07-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE49851E1 true USRE49851E1 (en) | 2024-02-27 |
Family
ID=55216719
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/517,790 Active USRE48687E1 (en) | 2014-07-29 | 2015-07-29 | Pyridinylaminopyrimidine derivatives, preparation process and use thereof |
US17/376,987 Active USRE49851E1 (en) | 2014-07-29 | 2015-07-29 | Pyridinylaminopyrimidine derivatives, preparation process and use thereof |
US15/329,044 Ceased US10072002B2 (en) | 2014-07-29 | 2015-07-29 | Pyridinylaminopyrimidine derivatives, preparation process and use thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/517,790 Active USRE48687E1 (en) | 2014-07-29 | 2015-07-29 | Pyridinylaminopyrimidine derivatives, preparation process and use thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/329,044 Ceased US10072002B2 (en) | 2014-07-29 | 2015-07-29 | Pyridinylaminopyrimidine derivatives, preparation process and use thereof |
Country Status (9)
Country | Link |
---|---|
US (3) | USRE48687E1 (en) |
EP (1) | EP3181560B1 (en) |
JP (1) | JP6431593B6 (en) |
KR (1) | KR101883125B1 (en) |
CN (1) | CN105315259B (en) |
CA (1) | CA2956628C (en) |
ES (1) | ES2855050T3 (en) |
PL (1) | PL3181560T3 (en) |
WO (1) | WO2016015453A1 (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105315259B (en) * | 2014-07-29 | 2018-03-09 | 上海艾力斯医药科技有限公司 | Pyridine amine pyrimidine derivates, its preparation method and application |
MY196809A (en) | 2015-12-24 | 2023-05-03 | Kyowa Kirin Co Ltd | (),()-unsaturated amide compound |
TWI726968B (en) | 2016-01-07 | 2021-05-11 | 開曼群島商Cs醫藥技術公司 | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase |
CN110590749B (en) * | 2016-03-07 | 2020-11-06 | 上海艾力斯医药科技股份有限公司 | Crystal form of pyridylamino pyrimidine derivative mesylate, preparation and application thereof |
CN107163026B (en) * | 2016-03-07 | 2019-07-02 | 上海艾力斯医药科技有限公司 | The salt and its preparation method and application of pyridine amine pyrimidine derivates |
WO2018019204A1 (en) | 2016-07-26 | 2018-02-01 | 深圳市塔吉瑞生物医药有限公司 | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity |
US11447471B2 (en) | 2017-06-23 | 2022-09-20 | Kyowa Kirin Co., Ltd. | α,β-unsaturated amide compound |
DE102017123894B3 (en) | 2017-10-13 | 2019-02-07 | Carl Zeiss Meditec Ag | Disc for HMD and HMD with at least one disc |
WO2019164945A1 (en) * | 2018-02-20 | 2019-08-29 | Dana-Farber Cancer Institute, Inc. | Pharmaceutical combinations of egfr inhibitors and methods of use thereof |
CN110606841A (en) * | 2018-06-15 | 2019-12-24 | 上海艾力斯医药科技有限公司 | Crystal form of pyridylamino pyrimidine derivative and preparation method thereof |
CN110606842B (en) * | 2018-06-15 | 2021-06-01 | 上海艾力斯医药科技股份有限公司 | Process for producing pyridylamino pyrimidine derivative and intermediate thereof |
CN110790749B (en) * | 2018-08-03 | 2023-07-14 | 北京普祺医药科技股份有限公司 | Nitrogen-containing heterocyclic compound, pharmaceutical composition and application thereof |
CN110857292A (en) * | 2018-08-22 | 2020-03-03 | 上海艾力斯医药科技有限公司 | EGFR kinase inhibitor and preparation method and application thereof |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
WO2020125391A1 (en) * | 2018-12-21 | 2020-06-25 | 深圳市塔吉瑞生物医药有限公司 | Aminopyrimidine compound used for inhibiting activity of protein kinase |
WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
CN111747950B (en) * | 2019-03-29 | 2024-01-23 | 深圳福沃药业有限公司 | Pyrimidine derivatives for the treatment of cancer |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
EP3974423A4 (en) * | 2019-05-22 | 2023-06-21 | Shanghai Hansoh Biomedical Co., Ltd. | Indole derivative-containing inhibitor, preparation method therefor and application thereof |
US11427567B2 (en) | 2019-08-14 | 2022-08-30 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors |
KR20220099970A (en) | 2019-10-11 | 2022-07-14 | 인사이트 코포레이션 | Bicyclic amines as CDK2 inhibitors |
CN110777391B (en) * | 2019-10-24 | 2021-01-22 | 浙江大学 | Electric reduction preparation method of gefitinib intermediate |
US20210161897A1 (en) | 2019-11-12 | 2021-06-03 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
US20230056604A1 (en) | 2020-01-20 | 2023-02-23 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
US20210369709A1 (en) | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
WO2022166916A1 (en) * | 2021-02-05 | 2022-08-11 | 深圳市塔吉瑞生物医药有限公司 | Substituted heteroaryl derivative, and composition and use thereof |
WO2023035223A1 (en) * | 2021-09-10 | 2023-03-16 | 上海艾力斯医药科技股份有限公司 | Pharmaceutical composition and use thereof |
CN113896716A (en) * | 2021-10-27 | 2022-01-07 | 浙江爱索拓科技有限公司 | Synthesis method of radioisotope carbon-14 double-labeled fulvestrant mesylate |
CN116159062A (en) * | 2021-11-24 | 2023-05-26 | 上海艾力斯医药科技股份有限公司 | Pharmaceutical composition and use thereof |
WO2023187037A1 (en) | 2022-03-31 | 2023-10-05 | Astrazeneca Ab | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer |
WO2023209090A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their application in the treatment of cancer |
WO2023209084A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer |
WO2023209086A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds for treating cancer |
WO2023209088A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their use in the treatment of cancer |
WO2024002938A1 (en) | 2022-06-27 | 2024-01-04 | Astrazeneca Ab | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
WO2024008929A1 (en) | 2022-07-08 | 2024-01-11 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer |
WO2024059962A1 (en) * | 2022-09-19 | 2024-03-28 | Shanghai Allist Pharmaceuticals Co., Ltd. | Pharmaceutical composition and use thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012061299A1 (en) | 2010-11-01 | 2012-05-10 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
CN102482277A (en) | 2009-05-05 | 2012-05-30 | 达纳-法伯癌症研究所有限公司 | Egfr inhibitors and methods of treating disorders |
WO2013014448A1 (en) | 2011-07-27 | 2013-01-31 | Astrazeneca Ab | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
CN104761544A (en) | 2014-01-03 | 2015-07-08 | 南京波尔泰药业科技有限公司 | Selectivity inhibitor of EGFR tyrosine kinase clinic important mutant |
WO2015188777A1 (en) | 2014-06-12 | 2015-12-17 | Shanghai Fochon Pharmaceutical Co Ltd | Certain protein kinase inhibitors |
US10472349B2 (en) | 2016-03-07 | 2019-11-12 | Shanghai Allist Pharmaceutical And Medical Tech Co | Salt of pyridinyl amino pyrimidine derivative, preparation method therefor, and application thereof |
US10550101B2 (en) | 2016-03-07 | 2020-02-04 | Shanghai Allist Pharmaceutical And Medical Tech Co | Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof |
USRE48687E1 (en) * | 2014-07-29 | 2021-08-17 | Shanghai Allist Pharmaceuticals Co., Ltd. | Pyridinylaminopyrimidine derivatives, preparation process and use thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103501612B (en) * | 2011-05-04 | 2017-03-29 | 阿里亚德医药股份有限公司 | The compound that cell is bred in cancer caused by suppression EGF-R ELISA |
-
2014
- 2014-07-29 CN CN201410365911.4A patent/CN105315259B/en active Active
-
2015
- 2015-07-29 US US16/517,790 patent/USRE48687E1/en active Active
- 2015-07-29 PL PL15828199T patent/PL3181560T3/en unknown
- 2015-07-29 US US17/376,987 patent/USRE49851E1/en active Active
- 2015-07-29 WO PCT/CN2015/000540 patent/WO2016015453A1/en active Application Filing
- 2015-07-29 ES ES15828199T patent/ES2855050T3/en active Active
- 2015-07-29 KR KR1020177005126A patent/KR101883125B1/en active IP Right Grant
- 2015-07-29 US US15/329,044 patent/US10072002B2/en not_active Ceased
- 2015-07-29 EP EP15828199.8A patent/EP3181560B1/en active Active
- 2015-07-29 CA CA2956628A patent/CA2956628C/en active Active
- 2015-07-29 JP JP2017504644A patent/JP6431593B6/en active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102482277A (en) | 2009-05-05 | 2012-05-30 | 达纳-法伯癌症研究所有限公司 | Egfr inhibitors and methods of treating disorders |
WO2012061299A1 (en) | 2010-11-01 | 2012-05-10 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
WO2013014448A1 (en) | 2011-07-27 | 2013-01-31 | Astrazeneca Ab | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
US20130053409A1 (en) | 2011-07-27 | 2013-02-28 | Astrazeneca Ab | 2-(2,4,5-substituted-anilino) pyrimidine compounds |
CN103702990A (en) | 2011-07-27 | 2014-04-02 | 阿斯利康(瑞典)有限公司 | 2-(2,4,5-substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
US8946235B2 (en) | 2011-07-27 | 2015-02-03 | Astrazeneca Ab | 2-(2,4,5-substituted-anilino) pyrimidine compounds |
CN104761544A (en) | 2014-01-03 | 2015-07-08 | 南京波尔泰药业科技有限公司 | Selectivity inhibitor of EGFR tyrosine kinase clinic important mutant |
WO2015188777A1 (en) | 2014-06-12 | 2015-12-17 | Shanghai Fochon Pharmaceutical Co Ltd | Certain protein kinase inhibitors |
USRE48687E1 (en) * | 2014-07-29 | 2021-08-17 | Shanghai Allist Pharmaceuticals Co., Ltd. | Pyridinylaminopyrimidine derivatives, preparation process and use thereof |
US10472349B2 (en) | 2016-03-07 | 2019-11-12 | Shanghai Allist Pharmaceutical And Medical Tech Co | Salt of pyridinyl amino pyrimidine derivative, preparation method therefor, and application thereof |
US10550101B2 (en) | 2016-03-07 | 2020-02-04 | Shanghai Allist Pharmaceutical And Medical Tech Co | Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof |
Non-Patent Citations (18)
Also Published As
Publication number | Publication date |
---|---|
CN105315259A (en) | 2016-02-10 |
US10072002B2 (en) | 2018-09-11 |
US20170210739A1 (en) | 2017-07-27 |
JP6431593B2 (en) | 2018-11-28 |
WO2016015453A1 (en) | 2016-02-04 |
CA2956628A1 (en) | 2016-02-04 |
KR20170031778A (en) | 2017-03-21 |
CN105315259B (en) | 2018-03-09 |
JP2017525685A (en) | 2017-09-07 |
PL3181560T3 (en) | 2021-06-14 |
EP3181560B1 (en) | 2020-11-25 |
EP3181560A4 (en) | 2017-12-27 |
EP3181560A1 (en) | 2017-06-21 |
JP6431593B6 (en) | 2019-01-09 |
CA2956628C (en) | 2018-10-23 |
USRE48687E1 (en) | 2021-08-17 |
ES2855050T3 (en) | 2021-09-23 |
KR101883125B1 (en) | 2018-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE49851E1 (en) | Pyridinylaminopyrimidine derivatives, preparation process and use thereof | |
JP7181558B2 (en) | Substituted 2-aminopyrimidine derivatives as EGFR modulators | |
US9758526B2 (en) | Quinoline-substituted compound | |
EP0802914B1 (en) | Aryl- and heteroaryl- purine and pyridopyrimidine derivatives | |
US11352341B2 (en) | 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof | |
US10377747B2 (en) | 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof | |
US11661397B2 (en) | 1,4-disubstituted imidazole derivative | |
US9550738B2 (en) | Bicyclic compounds as kinases inhibitors | |
US20220259235A1 (en) | EGFR Inhibitor, Composition, and Preparation Method Therefor | |
CN114269735A (en) | Dihydro or tetrahydro quinazoline compound and intermediate, preparation method and application thereof | |
US20170112833A1 (en) | Tyrosine Kinase Inhibitor And Uses Thereof | |
WO2013170770A1 (en) | Acetylene derivatives having antitumor activity | |
WO2013170671A1 (en) | Pteridine ketone derivative and applications thereof as egfr, blk, and flt3 inhibitor | |
US20150152088A1 (en) | Alkynyl heteroaromatic compound and use thereof | |
CN112638897B (en) | EGFR kinase inhibitor and preparation method and application thereof | |
WO2020125513A1 (en) | Macrocyclic compound as cdk inhibitor, preparation method therefor, and use thereof in medicine | |
WO2017211216A1 (en) | Fused pyrimidinopiperidine derivative, and manufacturing method and application thereof | |
WO2022171139A1 (en) | Macrocyclic compound, pharmaceutical composition, and use thereof | |
JP2024510312A (en) | Quinazoline compounds, compositions and applications of quinazoline compounds | |
CN116635390A (en) | Potent and selective compounds as serotonin 1B receptor modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FEPP | Fee payment procedure |
Free format text: PETITION RELATED TO MAINTENANCE FEES GRANTED (ORIGINAL EVENT CODE: PTGR); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: SHANGHAI ALLIST PHARMACEUTICALS CO., LTD., CHINA Free format text: CHANGE OF ADDRESS;ASSIGNOR:SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.;REEL/FRAME:063663/0430 Effective date: 20230516 |